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Introduction 
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Oral cancer is the sixth most common cancer worldwide and 
continues to be the most prevalent cancer related to the consumption of 
tobacco, alcohol and other carcinogenic substances. Oral squamous cell 
carcinoma (OSCC) accounts for nearly 50% of all newly diagnosed cancers 
in India. The prognosis of this cancer remains relatively unchanged for the 
past 30 years, despite advances in diagnosis and management.46  
The absence of definite early warning signs for most head and neck 
cancers suggests that sensitive and specific biomarkers are likely to be 
important in screening high-risk patients. Therefore, the dentist must 
consider all patients at risk and act accordingly in the history-taking and 
examination phases of the dental visit. By recognizing and establishing a 
diagnosis of oral cancer development in its early phase, the clinician can 
help the patient greatly increase his or her chances for a cure and a normal, 
full life. On the other hand, a much poorer outcome results when 
presentation and diagnosis are established at a later and more advanced 
stage. As clinicians, we can greatly influence disease outcome and quality of 
life when we confront oral mucosal alterations representing early squamous 
cell carcinoma in the patients.18, 36 
Salivary analysis holds promise as a non-invasive approach to 
identify biomarkers for human oral cancer. "Saliva is a mirror of our blood," 
said Wong. The salivary glands are exocrine glands that produce protein 
profiles indicative of the individual’s status at the moment of collection. 
 
 
Introduction 
 
2 
 
This potentially may be an advantage when seeking biomarkers for various 
diseases.47 
As a diagnostic fluid, saliva offers distinctive advantages over serum 
because it can be collected non-invasively by individuals with modest 
training. Furthermore, saliva may provide a cost-effective approach for the 
screening of large populations. Whole saliva (mixed saliva) is a mixture of 
oral fluids and includes secretions from both the major and minor salivary 
glands, in addition to several constituents of non-salivary origin, such as 
gingival crevicular fluid (GCF), expectorated bronchial and nasal secretions, 
serum and blood derivatives from oral wounds, bacteria and bacterial 
products, viruses and fungi, desquamated epithelial cells, other cellular 
components, and food debris. Analysis of saliva may be useful for the 
diagnosis of hereditary disorders, autoimmune diseases, malignant and 
infectious diseases and endocrine disorders, as well as in the assessment of 
therapeutic levels of drugs and the monitoring of illicit drug use.23 
Tumor markers that can be identified in saliva may be potentially 
useful for screening for malignant diseases. Salivary diagnosis may be part 
of a comprehensive diagnostic panel that will provide improved sensitivity 
and specificity in the detection of malignant diseases and will assist in 
monitoring the efficacy of treatment. Additional studies are certainly 
required to determine which salivary markers can be used for these 
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diagnostic purposes, and to determine their diagnostic value in comparison 
with other, more established, diagnostic tests. 23 
Salivary immunoglobulins play a role in host anti-tumor surveillance 
mechanisms. The predominant immunoglobulin in saliva is IgA. 
Approximately 90% of IgA in saliva is present as secretory IgA (S-IgA). S-
IgA has properties such as inhibition of bacterial adherence, neutralisation 
of toxins, and prevention of absorption of antigens through mucosal 
surfaces. It should be noted that there are often very large differences and 
variations in the content of S-IgA. Secretary immunoglobulin G (S-IgG) is 
present in saliva in very low quantities. The physiological and 
immunochemical characteristics are similar to those of serum IgG. It is 
thought that S-lgG may act within the mucosal epithelium and lamina 
propria to neutralise antigens and promote their phagocytosis once they have 
gained entry.74 
The Acute Phase Reactant Proteins (APRPs) are group of plasma 
proteins that alter their concentration in response to varied diseases. The 
levels of APRPs were shown to reflect events in tumour invasion and 
metastasis and were used in biochemical monitoring of cancer. Although 
extensive studies have been done in other cancers oral cancer has received 
less attention. These proteins are believed to play a role in regulation of the 
complex host response to malignancies.44 
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The salivary immunoglobulins and acute phase proteins levels may 
be altered in potentially malignant disorders and in oral carcinoma which 
may represent a local immunological attempt by the body to eliminate 
neoplastic cells.49  
Although various studies have been done to emphasize the role of 
serum immunoglobulins and acute phase proteins in oral carcinoma, very 
few studies are done to demonstrate the changes in the concentration of 
immunoglobulins and acute phase proteins in saliva of patients with 
potentially malignant disorders and oral carcinoma.   
This study deals with the salivary analysis to evaluate the 
immunological parameters ( IgA, IgG, C-reactive protein and haptoglobin) 
in the saliva of patients with potentially malignant disorders, oral squamous 
cell carcinoma (OSCC) and patients treated for oral squamous cell 
carcinoma. 
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AIM: 
To evaluate the prognostic value of salivary immunoglobulins and acute 
phase proteins in oral cancer. 
 
OBJECTIVES: 
1.  To determine the levels of IgA, IgG, C-reactive protein and haptoglobin 
in the saliva of patients with potentially malignant disorders.  
2. To determine the levels of IgA, IgG, C-reactive protein and haptoglobin 
in the saliva of patients with untreated oral squamous cell carcinoma. 
3. To determine the levels of IgA, IgG, C-reactive protein and haptoglobin 
in the saliva of patients with treated oral squamous cell carcinoma. 
4. To compare these levels with the control group. 
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The study is about the Evaluation of Salivary IgA, IgG, C- reactive 
protein and Haptoglobin in Potentially malignant disorders like Leukoplakia 
and Oral Submucous fibrosis, Oral cancer and Treated Oral cancer in 
comparison with healthy controls. The present literature review is about the 
various aspects of potentially malignant disorders - Leukoplakia and Oral 
Submucous Fibrosis, Oral cancer and their correlation with the salivary 
immunoglobulins and acute phase proteins levels.  
ORAL PRE CANCER AND ORAL CANCER   
The oldest description of human cancer was found in Egyptian 
papyri written between 3000-1500 BC. It referred to tumours of the breast.  
The oldest specimen of a human cancer was found in the remains of a 
female skull dating back to the Bronze Age (1900-1600 BC).The 
mummified skeletal remains of Peruvian Incas, dating back 2400 years ago, 
contained lesions suggestive of malignant melanoma. Evidence of cancer 
was found in fossilized bones and manuscripts of ancient Egypt.  Cancer is 
not a disease of our modern industrialized age, as some may have believed 
at one time.36 
           One of the earliest human cancers found in the remains of mummies 
was a bone cancer suggestive of osteosarcoma.  Louis Leakey in 1932 
found the oldest possible hominid malignant tumour from the remains of 
either a Homo erectus or an Australopithecus.  This tumour was suggestive 
of a Burkitt’s lymphoma (although that nomenclature was certainly not in 
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use then).  Diseases that we know to be rare cancers today have had a long 
history.36 
Hippocrates is credited with being the first to recognize the 
difference between benign and malignant tumours.  His writings describe 
cancers of many body sites.  The swollen blood vessels around the 
malignant tumours so reminded him of crab claws, he called the disease 
karkinos (the Greek name for crab).  In English this term translates to 
carcinos or carcinoma.36, 65 
The term tumour was originally applied to the swelling caused by 
inflammation. Neoplasm is a new growth that also may induce swelling, but 
by the long precedent the non – neoplastic usage had passed in limbo; thus 
the term is now equated with neoplasm.65 
Willis in 1952 described neoplasm as an abnormal mass of tissue, 
the growth of which exceeds and is uncoordinated with that of normal tissue 
and persists in the same excessive manner after cessation of the stimuli 
which evoked the change.65 
DEMOGRAPHICAL REVIEW 
Cancer is one of the major threats to public health in the developed 
world and increasingly in the developing world. In developed countries 
cancer is the second most common cause of death. According to the World 
Health Report 2004, cancer accounted for 7.1 million deaths in 2003 and it 
is estimated the overall number of new cases will rise by 50% in the next 20 
years.88 
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           There is a large geographical variation in oral cancer mortality. In the 
year 2000, oral cancer mortality rates were exceedingly high in some South 
Central Asian countries and Melanesia, where the rates were between 19 
and 22 per 100 000 habitants. In Africa, oral cancer mortality rates have 
been as high as 14⁄100 000. In Europe, Slovakia and Hungary were the 
nations with the highest mortality rates (7 and 11 per 100 000). In America, 
oral cancer mortality rates were high in Bolivia, Paraguay, Uruguay and 
Brazil, with rates between 3 and 4 per 100 000 habitants, whereas countries 
with lower mortality were Salvador, Nicaragua and Ecuador, with mortality 
rates of 0.2, 0.5 and 0.7 per 100 000, respectively. 28,89 
In Mexico, oral cancer mortality rates were higher than pharyngeal 
cancer mortality. This was in agreement with other studies from several 
populations of the world (Canada, Colombia, New Zealand, Germany, the 
United Kingdom, Switzerland, Finland, Singapore, Japan, Israel and India), 
and in some areas of the USA. However, in other countries where the 
incidence of oral pre-cancer is high, like Northern France or Slovenia, 
pharyngeal cancer in men is equal or even more frequent than oral cancer.27 
The prevalence of oral cancer is particularly high among men; oral 
cancer is the eighth most common cancer worldwide. Incidence rates for 
oral cancer vary in men from 1 to 10 cases per 100 000 population in many 
countries. In south-central Asia, cancer of the oral cavity ranks among the 
three most common types of cancer. In India, the age standardized incidence 
rate of oral cancer is 12.6 per 100 000 population.87 
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           In the South Asian region over one-third of tobacco consumed is 
smokeless. Traditional forms like betel quid, tobacco with lime and tobacco 
tooth powder are, commonly used and the use of new products is increasing, 
not only among men but also among children, teenagers, women of 
reproductive age, medical and dental students. In India, where chewing 
tobacco is used with betel nuts and reverse smoking (placing the lit end in 
the mouth) is practiced, there is a striking incidence of oral cancer- these 
cases account for as many as 50% of all cancers.88 
           India has the highest rate of oral cancer in the world, caused by 
tobacco consumption. WHO research indicates a 500 percent increase in 
cancer by 2025, of which 220 will be due to tobacco use. According to 
Women's Health in South East Asia (WHOSEA), almost one-half of all 
cancer cases in men and one-quarter of all cancer cases in women in India 
are believed to be tobacco-related.86  
Salonen  et al in 1990 68 reported on occurrence of oral mucosal 
lesions and the influence of tobacco habits in a randomly selected adult 
Swedish population. Nine hundred twenty (920, 95%) of the selected 
samples of 967 subjects comprising approximately 0.75% of the total adult 
population were examined; lesions were registered in 596 of the 920. The 
relationship between tobacco habits and mucosal lesions was analyzed and 
the time needed for treatment for the lesions was estimated. A positive 
correlation could be demonstrated between tobacco use and leukoplakia, 
frictional white lesion, coated tongue, hairy tongue and excessive melanin 
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pigmentation, while a negative correlation was observed for geographic 
tongue and aphthous ulcer. 
Sankaranarayanan in 199069 found that oral cancer ranks number 
one among all cancers in male patients and number three among cancers in 
female patients. Causal association between oral cancer and the chewing of 
betel quid containing tobacco leaves or stem and other tobacco habits has 
been extensively established. 
           Chakrabarti et al 199114 in a Calcutta population compared the 
prevalence of oral carcinoma and dysplasia in smokeless tobacco users and 
non-users. A total of 3205 subjects were studied. Of the smokeless tobacco 
users, 1.96% had oral carcinoma compared with 0.36% of non-users. The 
prevalence of oral dysplasia in the user's group was 14.4% as compared with 
6.85% in the group of non-users. 
           Warnakulasurya in 199182 reviewed the data on smoking and 
chewing habits that were prevalent in the rural population of SriLanka and 
provided an assessment of the risk from these habits for oral pre cancer. 
According to one study among 1133 villagers, 54% men, and 42% woman 
chewed betel quid out of which 46% of men and 63% of women  included 
tobacco. Tobacco was chewed alone by 2.6%. A community based case 
control study conducted on oral precancerous lesion and condition in a 
screening camp included 359 patients (316 men and 43 women) aged over 
20 years in whom the lesion was diagnosed and equal number of age and 
sex matched controls were included. The relative lowest risk of 5.3 among 
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men and 5 women were observed among chewers of betel quid without 
tobacco and were not significant. When the quid was chewed with tobacco 
the relative risk was 15 for men and 33 for women. Men who chewed betel 
quid with tobacco carried a higher risk than smokers (15 and 9.7 
respectively). However a higher relative risk of 24.7 was seen among men 
who both smoked and chewed indicating a synergistic action.       
Prabhu SR et al 199361 stated that oral cancer is currently the most 
frequent cause of cancer related death among Indian men, which is usually 
preceded by oral pre cancerous lesion like leukoplakia or condition like oral 
sub mucous fibrosis. 
           Gupta P.C. et al in 199834 conducted a house to house survey to 
investigate whether there was any increase in prevalence of oral submucous 
fibrosis (OSMF) and if so, could it be attributed to an increase in the use 
areca nut. A total of 11,262 men and 10,590 women aged 15 years and older 
were interviewed for their tobacco habits. Among 5018 men who reported 
the use of tobacco or areca nut, 164 were diagnosed as suffering from OSF 
with a prevalence of 3.2 %. Areca nut was used mostly in mawa; a mixture 
of tobacco, lime and areca nut and 10.9% of mawa users had OSF giving a 
relative risk of 75.6. The disease as well as areca nut use was concentrated 
in lower age group about 8.5% below 35 years and about 44% less than 25 
years. The authors concluded that an increase in the prevalence of OSF, 
especially in the lower age groups was directly attributable to the use of 
areca nut products. They also pointed that this increased prevalence of areca 
 
 
Review of  Literature 
  
 
12 
 
nut chewing and consequent increases in OSF was due to aggressive use of 
pan masala, which contains areca nut as a main constituent which may or 
may not contain tobacco.          
           Kayambe in 199943 performed a study in Congo and found low 
incidence of oral cancer compared to other countries. The relative frequency 
of oral cancer in Congo was about 2.1% and the palate was the most 
frequent site and squamous cell carcinoma was most common type of 
cancer. The most affected age group was between 50-59 years and women 
were more affected. 
          Crispian Scully et al in 200018 stated that the etiological factors of 
oral cancer (acting on a genetically susceptible individual) include tobacco 
use (75% of people with oral cancer smoke), betel use (Bidi leaf, and often 
tobacco, plus spices, slaked lime, and areca nut), alcohol consumption, a diet 
poor in fresh fruit and vegetables, infective agents (Candida, viruses), 
immune deficiency, and (in the case of lip carcinoma) exposure to sunlight. 
Jeng et al in 200141 stated that betel quid chewing is widely 
prevalent oral habit in India, Taiwan, Papua New Guinea, South Asia, and 
South Africa. It has been estimated that 600 million people chew betel quid 
worldwide. An average of 15 to 20 quid had been chewed by the betel quid 
users daily. A casual link between betel quid chewing and oral diseases such 
as oral leukoplakia, oral submucous fibrosis and oral cancer had been 
strongly established. 
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Zain et al in 200192 stated about the role of tobacco smoking, 
chewing of tobacco, areca nut, and betel quid and drinking of alcohol are 
established cultural risk factors of oral pre-cancer and oral cancer 
worldwide. A geographic and regional variation in the prevalence of oral 
pre-cancer and oral cancer indicates that the socio cultural life style plays an 
important role in the etiology and pathogenesis of the disease. 
Mehrota et al in 200351 stated that oral cancer was the commonest 
malignancy in Allahabad and the habit of chewing was particularly high 
among the oral cancer patients. The buccal mucosa was the most common 
site of oral cancer.  
Ranganathan et al in 200463 performed a case control study to 
ascertain the various habits, including chewing and oral submucous fibrosis 
in a selected hospital based population in Chennai, India. A total of 185 
consecutive patients with oral submucous fibrosis were matched with age 
and sex matched controls. There was a high preponderance of oral 
submucous fibrosis in males (9.9:1). Areca nut, pan masala and betel quid 
were associated with oral submucous fibrosis. Results showed that age, sex, 
smoking alone, alcohol use alone and smoking and alcohol alone were not 
associated with the development of oral submucous fibrosis. However the 
use of tobacco with alcohol with areca nut increases the risk. 
Sinha in 200477 stated that oral use of smokeless tobacco is widely 
prevalent in the South East Asia Region; the different forms include 
chewing, sucking and applying tobacco preparations to the teeth and gums. 
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In Southeast Asia over 250 million people use Smokeless tobacco products; 
about 17% of total population in Southeast Asia uses oral tobacco; of which 
95% belong to India (82%) and Bangladesh (13%) The global youth tobacco 
survey revealed high (10-20%) prevalence of smokeless tobacco use among 
young students (13-15 year)in Southeast Asia .Among disadvantaged youth 
group high (45%-71%) prevalence of tobacco use was reported in Southeast 
Asia . Tobacco is chewed in multiple forms in Southeast Asia, betel quid, 
leaf alone, leaf with lime and tobacco and areca nut preparation and tobacco 
water. Smokeless tobacco use varied from 7.2% to 59.4% in different states 
of India. In J & K, Goa, Himachal Pradesh, Haryana, Punjab, Kerala, 
Andhra Pradesh, Tamil Nadu, Delhi, Karnataka, Meghalaya, Rajasthan and 
West Bengal smoking prevailed over smokeless tobacco use while in 
Maharashtra, Uttar Pradesh, Sikkim, Madhya Pradesh, Assam, Orissa, 
Bihar, and Arunachal Pradesh smokeless tobacco use prevailed over 
smoking. In Gujarat, Manipur and Mizoram proportion of smoking and 
smokeless tobacco use, among males was almost equal (28.3 years. 29.4) 
while among female proportion was 5:1 (12.4% years. 2.5) in rural and 
urban areas respectively. 
Warnukulasurya in 200483 reviewed different types of smokeless 
tobacco habits all around the world and its role in occurrence of oral cancer. 
There are two main types of smokeless tobacco (ST), chewing tobacco and 
snuff. It may be used alone or in combination with other substances. 
Chewing tobacco comes in various forms, loose leaf, plug or twist. Loose 
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leaf or dry powdered tobacco is often mixed with various ingredients 
according to the local custom. Snuff is commercially made in many 
different forms from fine cut or ground tobacco and can be dry or moist. 
Moist snuff is marketed as loose snuff in containers or as sachets (portion-
bag). Many forms of ST are carcinogenic to humans and in animal studies. 
Cancer development at the site of placement and other oral mucosal lesions 
caused by these products has been described from several population 
groups.   
Durazzo et al in 200521 performed a study in Brazil on 374 patients 
with oral squamous cell carcinoma. Their ages varied from 14 to 94 years 
(mean = 57.4 years), with 255 men (68.2%), and 295 out of 366 Caucasian 
(80.6%). A majority had tumours of the tongue and or floor of mouth 
(55.6%), while 20.3% had lip cancer. Squamous cell carcinoma was found 
in 90.3%, and glandular carcinoma in 4%, T4 tumours in 39.6%, T1 lesions 
in 15.2% of all patients. Nearly 62% had no regional metastases, and the 
relative incidence in young patients (40 years or younger) reached 8.6%, 
and concluded that in spite of the predominance of locally advanced 
tumours, a majority of patients had no neck metastases. The 31.8% 
incidence in females indicates an increasing incidence of oral cavity cancer 
among women when compared to previous periods at the same institution. 
Neufeild  in 200556 and his co workers conducted a survey in India 
between 1995-96 constituting 4, 71,143 subjects and stated that the 
prevalence of alcohol consumption was present in 4.5%, smoking of tobacco 
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was present in 16.2% and chewing of tobacco was present in 14% of the 
study subjects. The prevalence of these habits was found to be more 
common among men and among the rural population with no formal 
education. 
Yi-Hsin-Yang et al in 200191 designed a population based survey to 
estimate the prevalence of oral submucous fibrosis (OSF), leukoplakia and 
various mucosal diseases and the usage of areca / betel quid chewing and to 
investigate the effects of areca / betel quid chewing on oral mucosal lesions 
in aboriginal community of Southern Taiwan. Three hundred and twelve 
people 20 years of age or older were included in the study. The areca / betel 
quid chewing habit was defined as chewing at least one quid a day for more 
than one month .Taiwan’s chewing quid included the fresh unripe areca 
fruit, as an essential ingredient while tobacco is never added .The 
prevalence of chewing areca /betel quid was 69.5%with an average of 17.3 
portions a day for an average of 24.4 years. More women (78.7%) than men 
(60.6%) chewed areca / betel quid .The prevalence of  OSF  was 17.6%, 
which was higher in women (19.5%) than in men (15.7%) while prevalence 
of leukoplakia was 24.4% with no difference between men and women .The 
prevalence of oral mucosal lesions increased as the years of chewing or 
daily consumption increased. It was found that the odds ratio for chewing 
areca / betel quid and having at least one of the above oral mucosal lesions 
was 8.21. Any additional smoking or drinking habits were not significant for 
having oral mucosal lesions. Gender was not a significant factor and age, 
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which was related to duration of chewing habit, had a significant impact on 
having lesions. The authors concluded that although the areca / betel quid in 
Taiwan does not contain any tobacco, a significant association was still 
identified between areca / betel quid chewing and oral mucosal lesions. 
Saraswathi et al in 200670 stated that the habit of smoking, drinking 
and chewing tobacco products were common oral habits in India and these 
habits were positively related with development of oral lesion such as 
OSMF, leukoplakia and oral lichen planus which had potential for 
malignant transformation. In their study the prevalence of the habit of 
smoking was higher in the age of 20-31 years and 40-51 years. Prevalence 
of alcohol consumption was higher in the 21-30 years age group and 
prevalence of the chewing habit was highest in the 51-60 years age group.   
Gunaseelan R et al in 200732 performed a community-based survey 
using qualitative methods. Out of 168 villages, 11 were randomly chosen. 
Fifteen in-depth interviews and five focus group discussions were 
conducted. Only those above 10 years of age and who used areca nut either 
in processed or un-processed form was included in the study. Among 
different forms of areca nut products, the use of Hans, which is a 
commercial flavoured product containing areca nut, tobacco and other 
ingredients is believed to be the most prevalent habit in all the age groups. 
Chewing areca nut is the initiating habit, leading to other habits such as 
smoking and consuming alcoholic beverages. Residents less than 30 years 
of age chew areca nut products for fun or because of peer pressure whereas 
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the 30 to 50 year olds get habituated due to reasons such as boredom and 
family problems. Although there is awareness regarding the ill-effects of 
tobacco use, there is not much awareness regarding areca nut. According to 
the residents, the community has not given enough thought regarding areca 
nut products and therefore no action has been taken to mitigate this high-risk 
behavior. It is the perception of the community that there is an increasing 
trend in the use of areca nut especially the commercial forms such as Hans, 
in rural TamilNadu.  
Gloria et al in 200829 studied 1914 villagers in Colombia for the 
effect of reverse smoking the oral mucosa.  Habit of smoking was present in 
501 (26%) inhabitants’ prevalence of reverse smoking was observed in 73 
(15%) of the inhabitant. From the 46 persons clinically studied, 42 (91.3%) 
were female, with an average age of 59.3 years old (range 29 -85), 41 
persons (89.1%) of the sample smokes tobacco, all of them combined their 
ways of smoking (conventional and reverse), the average number of 
tobaccos a day was 2.29 per day (range 1 – 7), and the average time that 
they have smoked was 30.83 years (range 1 – 65). In 20 (43.5%) cases both 
parents of the respondent were also in the habit of reverse smoking and the 
main motivations to acquire the habit were as follows: pleasure 21 (45.6%), 
not to smoke in the conventional way 8 (17.4%) and habit 7 (15.2%).  
Mathew et al in 200850 studied total of 1190 subjects who visited 
the department of oral medicine and radiology for diagnosis of various oral 
complaints over a period of 3 months were interviewed and clinically 
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examined for oral mucosal lesions. The result showed the presence of one or 
more mucosal lesions in (41.2%) of the population. Fordyce's granules was 
observed most frequently (6.55%) followed by frictional keratosis (5.79%), 
fissured tongue (5.71%), leukoedema (3.78%), smoker's palate (2.77%), 
recurrent aphthae, oral submucous fibrosis (2.01%), oral malignancies 
(1.76%), leukoplakia (1.59%), median rhomboid glossitis (1.50%), 
candidiasis (1.3%), lichen planus (1.20%), varices (1.17%), traumatic ulcer 
and oral hairy leukoplakia (1.008%), denture stomatitis, geographic tongue, 
betel chewer's mucosa and irritational fibroma (0.84%), herpes labialis, 
angular cheilitis (0.58%), and mucocele (0.16%). Mucosal lesions like 
tobacco-related lesions (leukoplakia, smoker's palate, oral submucous 
fibrosis, and oral malignancies) were more prevalent among men than 
among women. Denture stomatitis, herpes labialis, and angular cheilitis 
occurred more frequently in the female population.  
ORAL LEUKOPLAKIA 
In ancient literature leukoplakia was first described by Shushruta, in 
600 BC. who called it as Sanipataj Rog. Oral leukoplakia was first and fully 
described in the second half of the 19th century by the Hungarian 
dermatologist, Schwimmer (1877). Over the ensuing decades, oral 
leukoplakia has been recognized and established as a definitively 
precancerous lesion, often serving as the harbinger for the development of 
oral cancer, its importance lying in the general morbidity and high mortality 
rates associated with invasive cancer.40 
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Various studies have established a definitive role of tobacco in 
development of leukoplakia.  Gupta et al in 198433 stated that if there were 
no tobacco habit, there would be no leukoplakia. 
          Oral leukoplakia has been widely regarded as a pre cancerous lesion 
for many years. The term literally means white patch( Gk ‘leucos’ = white, 
‘plakia’ = patch ) and defined as a raised white patch of the oral mucosa 
measuring 5 mm or more, which cannot be scraped off and which cannot be 
attributed to any other diagnosable disease.60 
Definition Of Leukoplakia: 
In 1978 the World Health Organization collaborating centre for oral 
precancerous lesions defined leukoplakia as a white patch or  
plaque that cannot be characterized clinically or pathologically as any other 
disease. 
Axell T et al in 198406 at the first international conference on oral 
leukoplakia at Malmo, Sweden defined leukoplakia as a white patch or 
plaque that cannot be characterized clinically or pathologically as any other 
disease and is not associated with any physical or chemical causative agent 
except use of tobacco. 
Axell in 199407 defined leukoplakia as a predominantly white lesion 
of the oral mucosa that cannot be characterized as any other definable 
disease. 
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Pindborg in 199760 defined leukoplakia as a predominantly white 
lesion of the oral mucosa that cannot be characterized as any other definable 
lesion.  
Warnakulasurya in 200784 stated that leukoplakia should not be 
used to recognize white plaques of questionable risk having excluded (other) 
known diseases or disorders that carry no increased risk for cancer. 
Prevalence/ Incidence:  
Mehta FS et al in 196952 stated that males are predominantly 
affected but females are not immune. The male-to-female ratio was noted to 
vary enormously from district to district in India. In Gujarat and in Bihar, 
95–98% of leukoplakias were seen in males, whereas in Kerala and in 
Andhra Pradesh, the proportions of lesions seen in males were 80% and 
42%, respectively. 
           Axell T et al in 198706 found that white lesions were three times 
more common in males than in females. When proportioned according to 
probable etiology, the male to female ratio for tobacco-related leukoplakia 
was 6:1 while for idiopathic leukoplakia it was 5:2. 
           Jain et al in 199539 stated that incidence of oral leukoplakia was 
maximum in 5th and 6th decades of life. In a study conducted in Banaras, 
India 68 patients with oral leukoplakia with minimum age of 16 and 
maximum age of 67 are selected. Most common site for lesions was buccal 
mucosa (67.33% lesions) followed by labial mucosa (13.86% lesions) and 
tongue (11.88% lesions). Among three clinical types of leukoplakia; 
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homogenous type was present in 57.35% cases, verrucous type in 25% cases 
and speckled type in 17.65% cases. 26.48% patients were having oral 
submucous fibrosis along with leukoplakia lesions.  
Etiology: 
           Silverman, in 197575 found that in Gujarat, 15% of 57518 mill 
workers did not habitually use tobacco or areca nut and only 2% of the 16 
210 persons who had a mucosal lesion did not have a tobacco-related habit. 
The type of tobacco usage influences the distribution of the lesions: reverse 
cigar smoking causes lesions on the hard palate, chewing causes lesions at 
the site of quid placement and smoking of cheroots is associated with floor 
of mouth leukoplakia.  
Pindborg et al in 199760 examined 1866 individuals and found that 
chewing betel quid is more predominant in older age group and among 
women. 13.1% of all individuals examined showed chewers mucosa, 12.4% 
leukoedema, 1.8% preleukoplakia and 1.1% leukoplakia. Positive 
correlation between leukoedema, preleukoplakia and leukoplakia and habit 
of smoking where found.   
Wolfe et al in 198785 conducted a study among 226 Navajo Indians 
aged 14 - 19 years to assess the oral health effects of smokeless tobacco 
(ST). 64.2% of the subjects (75.4% of boys and 49% of girls) were users of 
ST and of these; over 95% used snuff alone or in combination with chewing 
tobacco. Leukoplakia was found in 40 subjects; 37 (25.5%) in ST users and 
3 (3.7%) in non-users 29.6% of the boys who used ST had leukoplakia as 
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compared with 17% of the girls. All leukoplakia were found in the 
mandibular arch. The mean duration of use was longer in users with 
leukoplakia than in those without (3.5years Vs.2.9 years). 81.1% of the 
users with leukoplakia used ST one or more days per week, compared to 
47.2% of those without leukoplakia. Thus the duration (in years) and 
frequency of ST use (days per week) were highly significant risk factors 
associated with leukoplakia. However the concomitant use of alcohol or 
cigarettes did not appear to increase the prevalence of these lesions. They 
concluded that in this study population, the odds of developing these lesions 
in users of ST were nearly nine times that of non users. 
Robertson in 199066 conducted a study on oral mucosal lesions in 
smokeless tobacco users. The risk for oral mucosal lesions associated with 
the use of smokeless tobacco among 1109 professional baseball players was 
investigated. Leukoplakia was very strongly associated with the use of 
smokeless tobacco in this population of healthy young men. Of the 423 
current smokeless tobacco users, 196 had leukoplakia compared to 7 of the 
493 non-users. The amount of ST used (in hours per day that ST was held in 
the mouth), investigated frequency of ST use (hours since last use), type 
(snuff vs. ST), and brand of snuff used were significantly associated with 
risk for leukoplakia lesions among ST users. 
ORAL SUBMUCOUS FIBROSIS 
Oral submucous fibrosis is a chronic disorder characterized by 
fibrosis of the lining mucosa of the upper digestive tract involving the oral 
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cavity, oropharynx and frequently the upper third of the oesophagus. Except 
in early forms of the disease the clinical presentation is characteristic due to 
fibrosis of lamina propria. 
Oral sub mucous fibrosis was first described by Schwartz in 1952 
under the term, atrophia idiopathia (tropica) mucosae oris. Lal in 1953 
described this condition as diffuse oral sub mucous fibrosis. Su in 1954 
described this condition as, idiopathic scleroderma of mouth. Rao and Behl 
in 1962 described this condition as idiopathic palatal fibrosis and sclerosing 
stomatitis respectively.61       
The pre cancerous nature of oral sub mucous fibrosis was first 
mentioned by Paymaster in 1956 who observed the development of slowly 
growing squamous cell carcinoma in one third of his oral sub mucous 
fibrosis patient. Since then several studies performed on various population 
of different ethnic origin with habit chewing betel quid essentially with 
areca nut, with or without tobacco supported precancerous nature of oral sub 
mucous fibrosis.61 
Definition of Oral Submucous Fibrosis: 
It is an insidious chronic disease affecting any part of the oral cavity 
and sometimes the pharynx, preceded by and/ or associated with vesicle 
formation, always associated with juxta-epithelial inflammatory reaction 
followed by a fibroelastic change of the lamina propria, with epithelial 
atrophy leading to stiffness of the oral mucosa and causing trismus and 
inability to eat.62 
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Prevalence: 
Gupta et al in 198033 calculated the incidence rate of OSF in 
Ernakulam, Kerala and found that it was 8 for men and 19 for women per 
100,000. 
Rajendran et al in 198662 did an epidemiological assessment of the 
prevalence of OSF among Indian villagers. He recorded a prevalence of 
0.2% (n=10071) in Gujarat, 0.04% (n=10169) in Andra Pradesh, 0.07% 
(n=20388) in Bihar, 0.4% (n=1027) in Kerala and 0.03% (n=101761) in 
Maharashtra. 
P.C.Gupta et al in 199834 reported the prevalence of Oral 
submucous fibrosis.  A house to house survey was conducted in Bhavnagar 
district, Gujarat state.  The use of areca nut containing products and tobacco 
was assessed through an interviewer administered questionnaire.  The oral 
examination was done by dentist.   
The diagnostic criterion for Oral sub mucous fibrosis was the 
presence of palpable fibrous bands.  An increase in the prevalence of Oral 
submucous fibrosis in lower socio-economic status groups was observed.       
Etiology: 
           Pindborg et al in 198459 performed a study on 100 subjects for their 
smoking and chewing habits and the condition of their oral mucosa. Out of 
100 subjects 44 were male and 56 female. The dominating habits in the male 
were areca nut chewing and cigarette smoking and areca nut chewing and 
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water pipe smoking in female population with no additional habit. The 
predominant occurrence of oral submucous fibrosis was seen.  
Rajendran.R in 198662 reviewed the etiology and pathogenesis of 
Oral submucous fibrosis.  According to him oral sub mucous fibrosis, a pre 
cancerous condition of the oral cavity has been studied by a number of 
workers in the field.  The available epidemiological data showed a clear cut 
geographical and ethnic pre dispositions, which suggested that certain 
customs or habits (chewing) prevalent among the population groups in 
South East Asia might be possible etiological factors.  However none of 
these customs was shown to be casually linked.  This led some workers to 
consider the importance of systemic pre dispositions, in addition to the 
effects of local factors on the oral mucosa.  More research is needed to 
elucidate this problem. 
Pindborg et al in 199559 reviewed the etiology of oral submucous 
fibrosis, a high risk pre cancerous condition, predominantly affecting 
Indians.  Conception of chilly was hypothesized as an etiologic factor on the 
basis of ecological observations and a solitary animal experimental study.  
Subsequent epidemiologic studies that included case-series reports, large 
cross-sectional surveys, case control studies, cohort and intervention studies 
have identified arecanut as the major etiologic factor.  The role of genetic 
susceptibility and that of autoimmunity are receiving attention currently.  
Influence of nutritional factors if any remains unclear.                     
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Reichart and Philipsen in 199864 reviewed the literature on betel 
chewer’s mucosa and reported the following findings. Betel chewer’s 
mucosa was first described and defined in 1971. The prelevance of the betel 
chewer’s mucosa varies between 0.2 % to 60% in different studies from 
south to South East Asia. Women are more affected than the men with 
buccal mucosa most commonly affected area along with the edentulous 
alveolar process, margin of tongue and the labial mucosa. It is often found 
with  leukodema and oral ulceration. The etiology of the lesion is traumatic 
and chemical and it is most likely not precancerous. Based on retrospective 
studies the authors suggested that betel chewer’s mucosa might be precursor 
of oral submucous fibrosis.  
Shah N, Sharma PP in 199873 conducted a study to identify the role 
of chewing and smoking habit in the etiology of oral submucous fibrosis. In 
this study 236 cases of oral submucous fibrosis were compared with 221 
control subjects matched for age, sex and socioeconomic conditions. It was 
found that chewing of areca nut, quid and pan masala was directly related to 
oral submucous fibrosis and not a single case was found without any 
chewing habit. The study showed that the pan masala chewers develop oral 
submucous fibrosis in half the time taken by areca nut betel quid chewers. It 
was also found that duration of chewing was not significantly correlated but 
the frequency of chewing was directly correlated to manifestation of oral 
submucous fibrosis. 
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Yang et al in 200190 found that although the areca/betel quid in 
Taiwan does not contain any tobacco, a significant association was still 
identified between areca/betel chewing and oral sub mucous fibrosis in 
ethnic Taiwanese aborigines. In a population based study conducted in 
southern Taiwan 320 subjects of 20 years of age or older were                                    
reviewed. The prevalence of oral submucous fibrosis and leukoplakia were 
17.6% and 24.4% respectively.       
Chen et al in 200217 found that HPV and betel quid chewing are the 
two most important factors associated with oral squamous cell carcinoma. In 
situ PCR ISH hybridization was performed on the tumour specimens from 
29 patients with oral squamous cell carcinoma and 29 mucosal specimens 
from normal healthy individuals. Their betel quid chewing and cigarette 
smoking habits are reviewed.   
Avon SL in 200405 described various oral mucosal lesions like oral 
submucous fibrosis in association with the use of quid. 
YANG et al in 200590 investigated the risk of areca / betel quid 
chewing with or without cigarette smoking on Oral submucous Fibrosis 
(OSF) and other oral mucosal lesions. A stratified case – control study was 
done which included 102 patients with oral mucosal lesions or OSF 
confirmed pathologically in the case group. They were separately analyzed 
for men and women investigating their risks. Age and sex matched 
individuals with no mucosal or lesions formed the control group. Among the 
102 patients, 76 (74.5%) are women &26 are men (25.5%). OSF was the 
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most prevalent disease (60.8%) followed by keratosis (39.2%) and epithelial 
hyperplasia (39.2%), squamous cell carcinoma in 9 cases and verrucous 
carcinoma in 2 cases. There were 73 of 102 patients (71.6%) with only area 
/ betel quid chewing habit and without any cigarette smoking habit. OSF 
was the most prevalent in combination of area / betel quid chewing and 
smoking habits, hyperkeratosis in chewing areca/ betel quid without 
cigarette smoking group and squamous cell carcinoma in the quid only 
group with higher prevalence of acanthosis in patients who chewed both 
betel quid &stem quid. For OSF, people with both smoking and chewing 
habits had a statistically significant odds ratio (OR) 8.68 and for people with 
chewing habit only and without any smoking habit the OR was 4.51. For 
other oral mucosal lesions, people with mixed habits and chewing only had 
significant risks (OR = 8.37 & 3.95 respectively). For both OSF and other 
oral lesions, the OR of mixed habits and chewing only were both higher in 
women than in men. Also it was found that the amount of more than 10-29 
and 30 and more counts of quids per day had significant odds ratio for both 
OSF and oral mucosal lesions. The areca / betel quid used in Taiwan does 
not contain any tobacco products and still a statistically significant 
association was found with oral mucosal lesions and OSF. 
Ahmad et al in 200602 conducted an etiological and epidemiological 
study of oral submucous fibrosis in Patna, Bihar. Total 157 cases of OSMF 
and 135 control subjects were selected for study in the period of 2002-2004. 
It was observed that male: female ratio was 2.7: 1. The youngest case of 
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OSMF was 11 year old and the oldest one was 54 years of age. Maximum 
numbers of cases were belonging to 21-40 years of age and they were 
belonging to low or middle socioeconomic class. Most of the OSMF cases 
used heavy spices and chillies, whereas control mild had spices and chillies. 
Gutkha was the most commonly used by the OSMF cases. Only 3 per cent 
did not use any gutkha or other areca nut product where as 80 per cent 
control did not have any chewing habit. The OSMF cases used gutkha and 
other products 2-10 pouches per day and kept in the mouth for 2-10 minutes 
and they were using since 2-4 years. Most of the OSMF cases kept gutkha in 
the buccal vestibule or they chewed and swallowed it, only a small number 
of patients chewed and spitted it out. It was also observed that OSMF 
developed on one side of the buccal vestibule where they kept the chew and 
other side was normal. 
TUMOR MARKERS 
Chan and Schwartz in 200215 defined tumour marker as a 
substance which can be measured in blood or other biological fluids and can 
be used to differentiate a tumour from normal tissue or to determine the 
presence of a tumour in a patient. A tumour marker can be produced by the 
tumour itself or by the host in response to a tumour.   
Measurement of tumour markers can be used to monitor cancer, 
predict the therapeutic response and prognosis of cancer, and in some 
certain situations even screen and diagnose for cancer. 
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The first identified cancer marker was monoclonal immunoglobulin 
light chain discovered by Bence-Jones in 1846. This Bence- Jones protein 
is still in clinical use in the diagnosis and prediction of the therapeutic 
response in cases of multiple myeloma.29 
The first modern tumour marker used to detect cancer was human 
chorionic gonadotropin (HCG), the substance doctors look for in pregnancy 
tests. Women whose pregnancy has ended but whose uterus continues to be 
enlarged are tested for the presence of HCG. A high level of HCG in the 
blood may indicate the presence of a cancer of the placenta called 
gestational trophoblastic disease (GTD).29 
The first success in developing a blood test for a common cancer 
was in 1965, when carcinoembryonic antigen (CEA) was found in the blood 
of some patients with colon cancer.29 
Diamandis et al in 200219 stated that subsequently the 
concentrations of many hormones, enzymes, and other proteins in biological 
fluids have been shown to reflect the presence of cancer in patients. Greg et 
al in 200331 described the role of serum tumour in early detection of various 
types of malignancy. 
An ideal tumour marker should be specific for a certain type of 
cancer and be sensitive enough to detect small tumours and thus permit 
early diagnosis. Unfortunately most tumour markers do not fulfill these 
criteria. 
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REVIEWS ON TUMOUR MARKERS: 
Hilkens et al in 198435 stated that large number of tumour markers 
have been used or proposed as markers for breast cancer. CA 15-3 is a 
carbohydrate antigen expressed in several glandular structures including the 
mammary gland.  
Björklund in 199008 stated that instead of the many epitopes 
recognized in the TPA assay, the tissue polypeptide-specific antigen (TPS) 
assay measures only the cell proliferation related epitope M3.  
Stenman et al. in 199178 stated that specificity could be clearly 
improved by measuring the proportion of the free PSA to PSA α1-
antichymotrypsin complex in addition to total PSA. 
Sundström and Stigbrand in 199479 measured Proteolytic 
fragments of cytokeratins 8, 18 and 19 in the tissue polypeptide antigen 
(TPA) assay.   
           Molina et al in 199554 stated that Carcinoembryonic antigen (CEA) 
levels in serum have been shown to be related to tumour size and nodal 
involvement of breast cancer. Simultaneous use of CEA and CA 15-3 allows 
early diagnosis of metastases in 60-80% of breast cancer patients. 
Eskelinen et al. 199424 and Eskelinen et al. 199725 stated that 
Serum TPA and TPS have been shown to have only limited value in the 
diagnosis of breast cancer.  
 
 
Review of  Literature 
  
 
33 
 
Fleisher et al. in 200226 stated that the Prostate-Specific Antigen 
(PSA) is the most important marker for the evaluation and even screening of 
prostate cancer. It is very sensitive but most of the patients with increased 
PSA values have benign prostatic hyperplasia.  
Fleisher et al. 200226 stated that serum CEA in colorectal cancer can 
be used to monitor the response to therapy and to document the progressive 
course of the disease. One of the most widely used tumor markers for 
gynecological cancers is CA 125 which is used for estimating the prognosis 
and monitoring of ovarian cancer and monitoring patients with endometrial 
cancer. However, serum CA 125 levels may be elevated also in benign 
gynecologic conditions and during the first trimester in normal pregnancy.  
Eliaz Kaufman et al23 stated that tumour markers that can be 
identified in saliva may be potentially useful for screening for malignant 
diseases. Salivary diagnosis may be part of a comprehensive diagnostic 
panel that will provide improved sensitivity and specificity in the detection 
of malignant diseases and will assist in monitoring the efficacy of treatment. 
Carmen Llena Puy et al in the year 200613 found that in some 
malignant diseases, markers can be detected in the saliva, such as the 
presence of protein p53 antibodies in patients with oral squamous cell 
carcinoma, or high levels of defensin-1 positively correlated with the serum 
levels. The presence of the c-erbB-2 tumour marker in the saliva and blood 
serum of breast cancer patients and its absence in healthy women is a 
promising tool for the early detection of this disease. In ovarian cancer too, 
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the CA 125 marker can be detected in the saliva with greater specificity and 
less sensitivity than in serum. 
Mahanz Saheb Jamee et al in the year 200748 found that the 
concentration of salivary IL-6 in oral squamous cell carcinoma patients was 
higher than control group. 
Ahmadi Motemayal et al in 201002 found elevated levels of 
salivary defencine – 1 to be indicative of the presence of oral squamous cell 
carcinoma. 
REVIEWS ON SALIVARY IMMUNOGLOBULINS (IgA & IgG) IN 
POTENTIALLY MALIGNANT DISORDERS (LEUKOPLAKIA / 
OSMF) 
Abrol in 197501 reported a rise in the salivary IgG levels in patients 
with oral submucous fibrosis. 
Phatak AG and Gosavi DK in 1975 and Phatak AG in 197958 
reported a rise in the serum and salivary IgG levels in patients with oral 
submucous fibrosis. 
Thomas Loning et al in 197981 found that the incidence of 
immunoglobulins (IgA and IgG) was twice as high in those cases of 
leukoplakia where dysplasia was present. 
Rajendran et al in 198662 found that there was no change in any of 
the immunoglobulin fractions in oral leukoplakia whereas a significant rise 
in IgA levels was observed in oral submucous fibrosis. 
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           Gupta Dinesh Chandra et al in 199233 reviewed on the etiological 
factors of oral submucous fibrosis and found that in addition to iron and 
vitamin deficiency there was a genetic predisposition and an elevation of the 
IgG levels in patients with oral submucous fibrosis.  
Krasteva.A et al in 200846 found that salivary IgA and IgG were 
significantly increased in patients with precancerous lesions.  
REVIEWS ON SALIVARY IMMUNOGLOBULINS (IgA & IgG) IN 
ORAL SQUAMOUS CELL CARCINOMA 
Mark.A et al in 197349 did a study in which the saliva of 260 
patients were analyzed for immunoglobulin content in which 35 patients 
were affected by primary oral cancer. He found that the highest IgA titers 
were seen in patients with oral and pulmonary cancers. 
Thomas Loning et al in 197981 found that the concentration of IgA 
and IgG decreased significantly with tumor dedifferentiation. 
Rajendran et al in 198662 found a significant rise in IgA levels in 
oral cancer patients but found no alterations in IgG levels. 
Rajendran and Vijayakumar et al in 198662 reported a rise in 
serum IgA in patients with oral squamous cell carcinoma and the levels 
were reported to be rising with the progression of the disease. These results 
reflect changes in the cell mediated immunity.  
Hu – De – En et al in 198738 found that there was a tendency for 
higher levels of immunoglobulins to be associated with more advanced 
stage of carcinoma. 
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Kashmoola et al in 200142 and Al-Rawi et al in 200503 had showed 
that patients with oral squamous cell carcinoma had markedly increased 
salivary total protein concentration which may be due to increasing salivary 
immunoglobulins. 
Robino Muchado de Souza et al in 200367 found that salivary IgA 
levels were reduced in cancer patients and were related to malnutrition, 
stress and tobacco. He found that the mean salivary IgA level was 17.0 ± 
10.4mg/dL in controls and 13.7± 3.9 mg/dL in oral cancer patients. 
Ashley M. Brown et al in 197504 stated that the IgA content of 
whole saliva of cancer patients was significantly elevated above that of 
controls. The results indicate that the elevated levels were attributable to 
leakage of serum factors through the damaged epithelium. 
Shpitzer.T et al in 200774 utilized comprehensive salivary analysis 
to evaluate biochemical and immunological parameters in the saliva of oral 
squamous cell carcinoma patients. He found that the concentration of 
salivary IgG was higher (125%) in oral squamous cell carcinoma patients 
while the concentration of secretory IgA was lower (45%). 
Krasteva.A et al in 200846 found that the salivary levels of IgA and 
IgG in patients with oral carcinoma were significantly increased. He stated 
that these findings reflect the local inflammation, accompanying the 
neoplastic process in the oral cavity. It could also be considered as being the 
local defense mechanism against tumour development. 
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REVIEWS ON SALIVARY IMMUNOGLOBULINS (IgA & IgG) IN 
TREATED ORAL SQUAMOUS CELL CARCINOMA 
Einhorn et al in 197222 observed elevated levels of IgG at the time 
of completion of radiotherapy and higher levels 3 months after radiotherapy. 
Elevated levels of IgG demonstrated an immune response which is helpful 
in antibody-dependant cytotoxic cell killing of tumour cells. This may 
represent enhanced immunization by antigens released during radiation 
induced tumour breakdown. 
Thomas Loning et al in 197981 found that the immunoglobulins 
(IgA and IgG) levels decreased after radiation therapy. 
Brown et al in 198111 found that following radiotherapy changes in 
specific agglutination titers of oral isolates reflected changes in saliva IgA. 
He found 13 patients with increased salivary IgA and 23 patients with 
decreased salivary IgA when he assessed 36 patients over a 30 month post-
irradiation period. 
           Hu De-En et al in 198738 reported that the levels of IgG decreased 
markedly after radiation therapy. 
           Jankovic.L et al in 199540 in his study on 40 patients with 
neoplastic disorders who have been treated has found that the mean IgG/IgA 
salivary ratio was 1.27 (normally below 1.0) due to an increased salivary 
concentration of IgG (mean 0.095 g/l), but also due to a decreased IgA 
concentration (mean 0.075 g/l); the IgG/IgA ratio in saliva was higher in 
patients with objective changes of the oral mucosa (1.53). 
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Meurman JH et al in 199753 found that the total salivary IgA 
decreased during cancer therapy which returned to the baseline level after 
termination of the treatment. 
           Krasteva.A et al in 200846 found that the salivary levels of IgG and 
IgA  remain significantly higher (p<0.05) in treated cancer patients. These 
findings reflect the local inflammation, accompanying the neoplastic 
process in oral cavity.  
REVIEWS ON ACUTE PHASE PROTEINS IN POTENTIALLY 
MALIGNANT DISORDERS, ORAL SQUAMOUS CELL 
CARCINOMA AND TREATED ORAL CARCINOMA 
Gallo.O et al in 199430 conducted a study in 18 patients with oral 
squamous cell carcinoma and found an increase in IL-6 which in turn 
induces the synthesis of CRP in head and neck carcinoma and plays a role in 
the regulation of the complex host response to malignancies. Significant (P 
< 0.0001) relationships were found between IL-6 and CRP (r = 0.69). 
          Dritan Turhani et al in 200520 has demonstrated an increase in the 
levels of CRP in oral squamous cell carcinoma patients. 
Krasteva.A et al in 200846 found that the salivary levels of 
haptoglobin and CRP were significantly higher in untreated oral squamous 
cell carcinoma. The high CRP levels are associated with tumour progression 
and poor survival. Increased levels of salivary haptoglobin could be related 
to direct transudation from the blood. He also stated that the CRP levels 
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remained higher in treated oral cancer patients and there was a significant 
decrease in the salivary haptoglobin in treated oral cancer patients. 
Kelly Powell in 200944 analysed 10,408 patients in which 1624 
patients had oral carcinoma. He found that patients with high baseline CRP 
(more than 3mg/L) had a 30 % greater risk of developing any cancer 
compared with those whose CRP was less than 1mg/L. 
Sunil.D.Khandavilli et al in 200980 did a study was designed to 
establish if elevated preoperative levels of CRP could predict the prognosis 
of patients treated with primary surgery for oral squamous cell carcinoma 
(SCC). Sixty patients with oral SCC who were treated by primary surgery 
and microvascular free flap reconstruction, were included in the study. The 
relation between preoperative levels of CRP, clinicopathological features 
and patient prognosis was determined.  
This study showed using bivariate analysis (p = 0.003) and 
multivariate analysis (p < 0.001) that a raised preoperative CRP was 
associated with worse overall survival. Tumour size and stage when 
combined with CRP levels increases the predictive power of this indicator. 
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Study topic: “Estimation of salivary immunoglobulins and acute phase 
proteins in patients with Potentially malignant disorders, Oral Cancer and 
Treated oral cancer” 
Study design:   The present study is a Randomized Control Study. 
Study duration: This study was conducted between April 2009 to May 
2010 in the department of Oral Medicine and Radiology of Ragas Dental 
College and Hospital, Dr. Rai Memorial Medical and Cancer Centre, 
Chennai. 
Study population:  
A total number of 80 patients were involved in the study. 
Obtaining approval from the authorities: 
Permission from the ethical committee of Ragas Dental College 
and Hospital, Chennai was obtained before starting the study.   
Due consent to participate in the study was obtained from the 
Subjects in letter format both in Tamil and English. 
MATERIALS  
Examination of the patient 
• Conventional Dental chair with halogen lamp 
• A pair of sterile gloves and disposable mouth mask 
• Stainless steel Kidney trays 
• Plain mouth mirror, straight probe, tweezer 
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• Sterile gauze pieces and cotton 
• Glass tumbler with water 
• 0.2% chlorhexidine gluconate 
• Sterilizer, cheatel forceps. 
• Sterile plastic containers for collection of saliva. 
METHODOLOGY: 
Study Group: 
The study group consists of a total number of 80 patients.  Out of the 
80 patients, 20 patients were suffering from Potentially malignant disorders 
like Leukoplakia and Oral submucous fibrosis, 20 patients were suffering 
from Oral cancer, 20 patients were treated for oral cancer and 20 were 
normal controls. 
Group I Potentially malignant disorder (Leukoplakia & Oral 
submucous fibrosis): 
This study group comprised of 20 patients visited the Department of 
Oral Medicine and Radiology.  Among these patients 18 were males and 02 
females with the age range from 21 – 75 years (mean 40.3 years) having 
Leukoplakia and Oral submucous fibrosis, diagnosed on the basis of clinical 
criteria. 
Clinical selection criteria: 
Leukoplakia: 60 
          Leukoplakia is defined as a grayish white lesion of the oral mucosa 
that cannot be characterized clinically as any other definable lesion.  It 
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appears as a white, elevated patch with a wrinkled surface. It can be 
homogeneous or non-homogeneous and can be as verrucous, papillary or 
nodular forms. On palpation the mucosa shows loss of suppleness, leathery 
with fissures called as cracked mud appearance and is rough in consistency. 
Oral Sub Mucous Fibrosis: 34 
           The patients were graded into one of the following 6 grades: 
Grade I  – Only blanching of the buccal mucosa without symptoms. 
Grade II    – Burning sensation, dryness of mouth, vesicles or ulcers in 
    the mouth without tongue involvement. 
Grade III   – In addition to grade II there is restriction of mouth opening. 
Grade IV   – In addition to grade III palpable bands all over the mouth            
    without tongue involvement. 
Grade V     – Grade IV plus tongue involvement. 
Grade VI   – Oral submucous Fibrosis with histologically proven oral  
     cancer. 
Group II (Oral Cancer): 
This study group consists of 20 patients suffering from oral cancer 
diagnosed clinically. These patients were selected from the Department of 
Oral Medicine and Radiology, Dr.Rai Memorial Medical and Cancer center 
and Cancer shelter. Among these patients 15 were males and 05 females 
with the age range from 33  –  68 years (mean 48.45 years). 
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Clinical Selection Criteria: 
 Presence of a non – healing ulceroproliferative growth with pain, 
tenderness, limitation / loss of function, bleeding and indurated margins. 
Presence of regional lymphadenopathy.  
Group III (Treated Oral Cancer):  
This study group consists of 20 patients who have been treated for 
oral squamous cell carcinoma. These patients were selected from Dr.Rai 
Memorial Medical and Cancer center. Among these patients 14 were males 
and 06 were females with the age range from 24 - 69 years (mean 44.25 
years).  
Clinical Selection Criteria: 
• Patients who have been treated for oral carcinoma. 
• Patients who clinically shows no signs of carcinoma.  
Group IV (Controls): 
The control group comprises of 20 normal individuals who visited 
the outpatient department of Oral Medicine and Radiology.  Among them, 
15 were males and 05 females with the age range from 19 – 68 years (mean 
40.5 years). Thus the control groups were matched with age and sex of the 
study group.   
Clinical Selection Criteria: 
• Patients who donot have any mucosal lesions. 
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• Individuals who are apparently healthy with no history of Diabetes, 
Hypertension and any known diseases.   
Informed consent: 
Informed consent was taken from all subjects before including them 
in the study.  
Exclusion criteria: 
          Participants with infectious diseases during one month before saliva 
sampling, active dental abcesses, and collagen vascular diseases were 
excluded from the study. 
Examination of the subjects: 
The experimental subjects were made to sit comfortably on a dental 
chair. Sterile hand gloves were used during examination of the patients.  
Patients were examined under halogen lamp in the dental chair under aseptic 
conditions and relevant demographic data were collected.  Clinical diagnosis 
was made and patients who showed characteristic features of Leukoplakia, 
Oral submucous fibrosis and Oral Cancer were prepared for sample 
collection. 
Saliva sample collection: 
The subjects were required to abstain from eating, drinking, smoking 
or using oral hygiene products for at least 1 hour before saliva collection.  
The patients were asked to rinse their mouth with water and were made to 
sit comfortably in a dental chair. Saliva was collected during a 15-minutes 
interval by spitting method. This was pooled saliva and represented the 
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output from all the salivary glands. 2-3mL of saliva was collected in sterile 
containers. 
All samples were kept in ice after collection and then centrifuged at 
3000 rpm for 10 min to remove particulate materials and the supernatant 
was used for estimation of the immunoglobulins and acute phase proteins. 
 
QUANTITATIVE DETERMINATION OF SALIVARY 
IMMUNOGLOBULIN A BY ELISA METHOD. 37 
Principle: 
Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) was used for the  
quantitative determination of secretory IgA in saliva. In a first incubation 
step, the sIgA in the samples is bound to polyclonal antibodies (rabbit anti 
human IgA), which are immobilized to the surface of the microtiter wells. 
To remove all unbound substances, a washing step is carried out. In a 
second incubation step, a Peroxidase-labeled conjugate (mouse anti-sIgA) is 
added which recognizes specifically the bound secretory IgA. After another 
washing step, to remove all unbound substances, the solid phase is 
incubated with the substrate, Tetramethylbenzidine (TMB). An acidic stop 
solution is then added to stop the reaction. The color converts from blue to 
yellow. The intensity of the yellow color is directly proportional to the 
concentration of secretory IgA. A dose response curve of the absorbance 
unit (optical density, OD) vs. concentration is generated, using the results 
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obtained from the calibrators. Secretory IgA in the patient samples is 
determined directly from this curve. 
 
 
Reagents: 
 
 
Saliva collection and preparation: 
• No food or liquid should be consumed 30 min before sample 
collection. 
• The samples were centrifuged at 3000 rpm for 10 min. Sample 
supernatant was stored at -20°C. 
• For analysis, the supernatant was diluted 1:2000 in ELISA wash 
buffer, e.g.10 μl supernatant + 990 μl wash buffer; diluted the 
obtained solution again: 50 μl diluted supernatant + 950 μl wash 
buffer. 100 μl of the final dilution per well was used. 
Procedure: 
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              The precoated PLATE (microtiter plate) 5 x was washed with 250 
μl ELISA wash buffer. The tests were carried out in duplicate. 
1. 100 μl STD (standards), CTRL (control) and patient samples were 
added.  
2. Incubated for 1 hour, shaking on a horizontal mixer, at room 
temperature. 
3. Aspirated and washed the wells 5 x with 250 μl ELISA wash buffer. 
4. 100 μl CONJ (conjugate; POD antibody) was added. 
5. Incubated for 1 hour, shaking on a horizontal mixer, at room 
temperature. 
6. Decanted the content of the plate and the wells 5 x  were washed with 
250 μl of wash buffer. 
7. 100 μl SUB (TMB substrate) was added. 
8. Incubated for 10-20 minutes at room temperature. 
9. 50 μl STOP (ELISA stop solution) was added and mixed shortly. 
10. Absorption was determined with an ELISA reader at 450 nm against 620 
nm as reference.  
For the calculation of the saliva values, the results from the microplate 
reader was multiplied by 2.000. 
Range: 
Children (n=37) 18 - 237μg/ml (mean 128 μg/ml) 
Age >16 years (n=33) 102 - 471 μg/ml 
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QUANTITATIVE  DETERMINATION OF SALIVARY 
IMMUNOGLOBULIN G BY IMMUNOTURBIDOMETRIC METHOD. 37 
Principle: 
Anti-human IgG antibodies when mixed with samples containing 
IgG form insoluble complexes. These complexes cause an absorbance 
change, dependent upon the IgG concentration of the patients sample, that 
can be quantified by comparison from a calibrator of known IgG 
concentration. 
Reagents: 
Diluent (R1)     - Tris buffer 20mmol/L, PEG 8000, pH 8.3. 
                               Sodium azide 0.95g/L. 
Antibody (R2)  -     Goat serum, anti-human IgG, pH 7.5. 
                               Sodium azide 0.95g/L. 
Calibration curve: 
The following PROT CAL calibrator dilutions in NaCl 9g/L as 
diluent was prepared. The concentration of the IgG calibrator was multiplied 
by the corresponding factor stated in the table below to obtain the IgG 
concentration of each dilution. 
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Calibrator Dilution 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Calibrator (µL) 
NaCl 9g/L (µL) 
- 
100 
10 
90 
25 
75 
50 
50 
75 
25 
100 
- 
 
Factor 
 
0 
 
0.1 
 
0.25 
 
0.5 
 
0.75 
 
1.0 
 
         Equipment: 
• Thermostatic bath at 37ºC. 
• Spectrophotometer, thermostatable at 37ºC with a 600nm filter 
(580-620nm). 
Procedure: 
1. The reagents and the photometer (cuvette holder) were brought to 37ºC.  
2. Assay conditions:  
Wavelength :             600 nm  
Temperature :           37 ºC  
Cuvette light path :   1cm  
3. The instrument was adjusted to zero with distilled water. 
4.  Pipetted into a cuvette:  
                   Reagent R1 (μL)                           -        800 µL 
                   Sample or Calibrator (μL)            -          10 µL 
5. The reagents were mixed and the absorbance (A1) was read after the 
sample addition. 
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6. Immediately, pipetted into the cuvette: 
             Reagent R2 (μL)                           -        200 
7. The reagents were mixed and the absorbance (A2) of calibrators and 
sample were read exactly 2 minutes after the R2 addition. 
Calculations: 
The absorbance difference (A2-A1) of each point of the calibration 
curve was calculated and the values obtained were plotted against the IgG 
concentration of each calibrator dilution. IgG concentration in the sample 
was calculated by interpolation of its (A2-A1) in the calibration curve. 
Reference value: 
700 – 1600mg/dL.  
Upto 3000mg/dL. 
Detection limit: 
Values less than 10.3mg/dL give non-reproducible results. 
 
QUANTITATIVE DETERMINATION OF SALIVARY C-REACTIVE 
PROTEIN BY IMMUNOTURBIDOMETRIC METHOD 37 
Principle: 
          Latex particles coated with specific anti- human CRP are agglutinated 
when mixed with samples containing CRP. The agglutination causes an 
absorbance change, dependent upon the CRP contents of the patient sample 
that can be quantified by comparison from a calibrator of known CRP 
concentration. 
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Clinical Significance 
CRP is an acute-phase protein present in normal serum, which 
increases significantly after most forms of tissue injuries, bacterial and virus 
infections, inflammation and malignant neoplasia. During tissue necrosis 
and inflammation resulting from microbial infections, the CRP 
concentration can rise up to 300 mg/L in 12-24 hours 
Reagents: 
 
Diluent – ultra (R1) 
 
Tris buffer 20mmol/L, pH 8.2. 
Sodium azide 0.95g/L 
 
Latex – ultra (R2) 
 
Latex particles coated with goat IgG anti human 
CRP, pH 7.3, Sodium azide 0.95g/L 
 
U-CRP CAL 
 
Calibrator, C-Reactive protein concentration is 
stated on the vial label. 
 
        Preparation: 
• Working reagent - The latex vial was gently shaken. 1mL latex 
reagent + 14mL diluent. 
• CRP Calibrator - Reconstituted with 2.0mL of distilled water. Mixed 
gently and brought to room temperature before use.  
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Calibration Curve: 
Prepared the following CRP Calibrator dilutions in NaCl 9 g/L as 
diluent. Multiplied the concentration of the CRP calibrator by the 
corresponding factor stated in table below to obtain the CRP concentration 
of each dilution. 
 
Calibrator Dilution 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Calibrator (µL) 
NaCl 9g/L (µL) 
- 
100 
10 
90 
25 
75 
50 
50 
75 
25 
100 
- 
 
Factor 
 
0 
 
0.1 
 
0.25 
 
0.5 
 
0.75 
 
1.0 
 
Equipment: 
• Thermostatic bath at 37ºC. 
• Spectrophotometer,  thermostatable at 37ºC with a 540nm filter 
(530-550nm). 
Procedure: 
1. The working reagent and photometer (cuvette holder) were brought 
to 37 ºC. 
2. Assay conditions: 
         Wavelength :             540nm (530-550) 
         Temperature :            37ºC 
         Cuvette light path :   1cm. 
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3. The instrument was adjusted to zero with distilled water. 
4. Pipetted into a cuvette: 
       Working reagent (mL)       -   1.0 
        Calibrator                          -   1.0 
5. The reagents were mixed and the absorbance (A1) was read 
immediately and after 4 minutes of sample addition (A2) was read. 
Calculations: 
The absorbance difference (A2-A1) of each point of the calibration 
curve was calculated and the values obtained were plotted against the CRP 
concentration of each calibrator dilution. CRP concentration in the sample 
was calculated by interpolation of its (A2-A1) in the calibration curve. 
Detection Limit: 
Values less than 0.05mg/L give non-reproducible results. 
 
QUANTITATIVE DETERMINATION OF SALIVARY 
HAPTOGLOBIN BY IMMUNOTURBIDOMETRIC METHOD.37 
Principle: 
HAPTO is a quantitative turbidimetric test for the measurement of 
haptoglobin in human serum or plasma. Anti-haptoglobin antibodies when 
mixed with samples containing haptoglobin, form insoluble complexes. 
These complexes cause an absorbance change, dependent upon the 
haptoglobin concentration of the patient sample, that can be quantified by 
comparison from a calibrator of know haptoglobin concentration.  
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Clinical Significance  
The haptoglobin is an α2-glycoprotein synthesized in the liver that 
binds hemoglobin irreversibly. The hapto-hemoglobin complexes, as well 
free haptoglobin itself, play significant roles in the iron storage and prevents 
of possible renal damage as a consequence of hemoglobin excretion. As an 
acute-phase protein, haptoglobin is increased in the presence of acute 
inflammatory process, tissue necrosis or malignancy.  
Reagents: 
 
Diluent (R1) 
 
Tris buffer 20 mmol/L, PEG 8000, pH 8.2.  
Sodium azide 0.95 g/L.  
 
Antiserum (R2) 
Goat serum, anti-human haptoglobin pH 7.5. 
Sodium azida 0.95 g/L. 
 
Calibration Curve:  
Prepared the following PROT CAL Calibrator dilutions in ClNa 9 
g/L as diluent. Multiplied the concentration of the haptoglobin calibrator by 
the corresponding factor stated in table bellow to obtain the haptoglobin 
concentration of each dilution. 
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Calibrator Dilution 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
Calibrator (µL) 
NaCl 9g/L (µL) 
- 
100 
10 
90 
25 
75 
50 
50 
75 
25 
100 
- 
 
Factor 
 
0 
 
0.1 
 
0.25 
 
0.5 
 
0.75 
 
1.0 
Procedure: 
1. Brought the reagents and the photometer (cuvette holder) to 37ºC.  
2. Assay conditions:  
Wavelength  : 340 nm  
Temperature  : 37 ºC  
Cuvette light path : 1cm  
3. Adjusted the instrument to zero with distilled water. 
4.  Pipetted into a cuvette:  
                     Reagent R1 (μL)                     -        800 µL 
                     Sample or Calibrator (μL)        -          10 µL 
5. Mixed and read the absorbance (A1) after the sample addition. 
6. Immediately, pipetted into the cuvette: 
              Reagent R2 (μL)                    -        200 
7. Mixed and read the absorbance (A2) of calibrators and sample 
exactly 2 minutes after the R2 addition. 
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Calculation: 
The absorbance difference (A2-A1) of each point of the calibration 
curve was calculated and the values obtained were plotted against the 
haptoglobin concentration of each calibrator dilution. Haptoglobin 
concentration in the sample was calculated by interpolation of its (A2-A1) in 
the calibration curve. 
 
Range: 30 – 200 mg/dL. 
Detection Limit: 
Values less than 1.3mg/dL give non-reproducible results. 
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Statistical Analysis: 
Mean and standard deviation were estimated in the sample for each 
study group.  Mean values were compared by using one-way ANOVA 
followed by multiple range tests by Tukey-HSD procedure. 
In the present study P <0.05 was considered as the level of significance.  
                                                       
   
Where Xi is the individual observation and n is the sample size. 
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CASE SHEET PROFOMA 
 
RAGAS DENTAL COLLEGE & HOSPITAL, 
2/102, EAST COAST ROAD, UTHANDI, CHENNAI – 600 119. 
DEPARTMENT OF ORAL MEDICINE RADIOLOGY 
 
ESTIMATION OF SALIVARY IMMUNOGLOBULIN AND ACUTE 
PHASE PROTEINS IN PATIENTS WITH POTENTIALLY 
MALIGNANT DISORDERS, UNTREATED AND TREATED ORAL 
CANCER. 
 
Serial no.                                                                Op. no.   
Name:                                                                     Age/ Sex:   
Religion:  
Occupation:                                                            Income:  
Address:                                                                  Phone no:  
   
   
HABITS 
 
PRESENT 
 
ABSENT 
 
Smoking 
    
 
Chewing 
    
 
Alcohol 
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          LESION 
   
PRESENT
   
ABSENT
Potentially malignant 
disorders 
    
Untreated Oral 
Squamous Cell 
Carcinoma 
    
Treated Oral Squamous 
Cell carcinoma 
    
   
Date of sample collection:  
PARAMETERS/  
            
      LESION 
SALIVARY  
IgA  
(mg/l) 
SALIVARY  
IgG  
(mg/l) 
SALIVARY  
CRP  
(mg/l) 
SALIVARY 
HAPTOGLOBIN  
(mg/l) 
Potentially malignant 
disorders 
        
Untreated Oral 
Squamous Cell 
Carcinoma 
        
Treated Oral 
Squamous Cell 
carcinoma 
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FIGURE 1: ARMAMENTARIUM FOR CLINICAL 
EXAMINATION 
 
 
 
 
 
 
 
FIGURE 2: NORMAL MUCOSA 
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FIGURE 3: CLINICAL LESION - LEUKOPLAKIA 
 
 
 
 
 
 
 
 
 
FIGURE 4: CLINICAL LESION – ORAL SUBMUCOUS 
FIBROSIS 
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FIGURE 5: CLINICAL LESION – ORAL CANCER 
 
 
 
 
 
 
 
 
FIGURE 6: CLINICAL LESION – ORAL CANCER 
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FIGURE 7: MATERIALS FOR SAMPLE COLLECTION 
 
 
 
 
 
FIGURE 8: MATERIALS FOR BIOCHEMICAL ANALYSIS 
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FIGURE 9: SPECTROPHOTOMETER 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10: ELISA READER AND WASHER 
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Table 1 and Graph 1 show Distribution of the subjects by Sex: 
The study group consisted of a total number of 80 patients. Out of 
the 20 (100%), patients in Group I 18 (90%) were males and 2 (10%) were 
females. In Group II among the 20 (100%), subjects 15 (75%) were males 
and 5 (25%) females. In Group III among the 20 (100%), patients, 14(60%) 
were males and 6(40%) were females. Among the 20 (100%), subjects in 
Group IV, 15 (75%) were males and 5 (25%) were females. In total among 
the 80 (100%), 62 (77.5%) were males and 18 (22.5%) were females. 
The sex wise distribution of subjects were found to be statistically 
non significant, which means that both the experimental and control 
subjects were similar with respect to sex in distribution with p value 0.46. 
Table 2 and Graph 2 show Distribution of the subjects by Age: 
The subjects were divided into six age groups which are as follows: 
15-25 years, 26-35 years, 36-45 years, 46-55 years, 56-65 years and above 
65 years. Among the 20 (100%),  in group I, 5(25%) were between 15-25 
years, 4(20%) between 26-35 years, 5(25%) were between 36-45 years, 
2(10%) between 46-55years, 1(5%) between 56-65 years and 3(15%) were 
above 65 years. Among the 20 (100%), in group II none were in the age 
group of 15-25 years, 2(10%) between 26-35 years, 8(40%) were between 
36-45 years, 4(20%) were between 46-55 years, 5(25%) were between 56-
65 years and 1(5%) above 65 years. In group III, among the 20 (100%), 
1(5%) belonged to 15-25 years, 3(15%) belonged to 26-35 years, 7(35%) 
belonged to 36-45 years, 4(20%) belonged to 46-55 years, 3(15%) belonged 
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to 56-65 years and 2(10%) belonged to age group of above 65 years. Among 
the 20 (100%), in group IV 3(15%) were in the age group of 15-25 years, 
5(25%) between 26-35 years, 6(30%) were between 36-45 years, 2(10%) 
were between 46-55 years, 3(15%) were between 56-65 years and 1(5%) 
above 65 years. In total among the 80(100%), 9(11.25%) were between 15-
25 years, 14(17.5%) between 26-35 years, 26(32.5%) were between 36-45 
years, 12(15%) between 46-55years, 12(15%) between 56-65 years and 
7(8.75%) were above 65 years. The age wise distribution of subjects were 
found to be statistically not significant, which means that both the 
experimental and control groups were similar with respect to age 
distribution with p value 0.111. 
Table 3 and Graph 3 show Distribution of the subjects based on the 
habits: 
The distributions of habits were grouped as follows, smoking, 
chewing, chewing and smoking, smoking and alcohol, chewing and alcohol, 
and chewing, smoking and alcohol.  
In group I among the 20 (100%), subjects, 4(20%) had the habit of 
smoking, 8(40%) had the habit of chewing, 4(20%) had the habit of chewing 
and smoking while 3(15%) had the combined habits of smoking and alcohol 
consumption, 1(5%) had the habit of chewing and alcohol consumption and 
none had all three habits together.  
In group II among the 20 (100%), subjects, 5(25%) had the habit of 
smoking, 7(35%) had the habit of chewing, 3(15%) had the habit of chewing 
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and smoking while 3(15%) had the combined habits of smoking and alcohol 
consumption, none had the habit of chewing and alcohol consumption and 
2(10%) had all three habits together.  
In group III out of the 20 (100%), subjects, 6(30%) had the habit of 
smoking, 6(30%) had the habit of chewing, 4(20%) had the habit of chewing 
and smoking, 3(15%) had the habit of smoking and alcohol consumption, 
none had the habit of chewing and alcohol consumption and 1(5%) had all 
three habits together.  
In group IV among the 20 (100%), subjects, 11(55%) had no 
deleterious habits, 5(25%) had the habit of smoking, 2(10%) had the habit of 
chewing, 1(5%) had the habit of chewing and smoking, 1(5%) had the habit 
of smoking and alcohol consumption, none had the habit of chewing and 
alcohol consumption and none had all three habits together.  
In total among the 80 (100%), 11(13.8%) had no deleterious habits, 
20(25%) had the habit of smoking, 23(28.8%) had the habit of chewing, 
12(15%) had the habit of chewing and smoking, 10(12.5%) had the habit of 
smoking and alcohol consumption, 1(1.3%) had the habit of chewing and 
alcohol consumption and 3(3.8%) had all three habits together. The 
distributions of subjects based on habits were found to be statistically 
significant, with the p value 0.000. 
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Table 4 and Graph 4 show Distribution of the subjects according to the 
lesion in group – I: 
The subjects in Group – I were divided into two classes based on the 
type of potentially malignant disorder present as follows, Leukoplakia and 
Oral submucous fibrosis. Among the 20 (100%), subjects in Group I, 
9(45%) had Oral submucous fibrosis and 11(55%) had Leukoplakia. The 
group is constant and hence the p-value is not attained. 
Table 5 and Graph 5 show Distribution of the subjects according to the 
site of Leukoplakia in Group – I: 
In Group I among the total of 20 (100%) subjects, 11(55%) had 
leukoplakia in which 7(63.6%) were present in the retro-commissure area, 2 
(18.2%) in the buccal mucosa, 1(9.1%) in the tongue and 1(9.1%) in the 
floor of the mouth.  The group is constant and hence p-value is not attained. 
Table 6 and Graph 6 show Distribution of the subjects according to the 
grades of OSMF in Group – I: 
In Group I 9(45%) subjects out of the total of 20(100%) had OSMF 
with 5(55.6%) in Grade III, 2(22.2%) in Grade I, 2(22.2%) in Grade IV and 
none in Grade II. The p-value is not attained as the group is constant. 
Table 7 and Graph 7 show Distribution of the subjects according to the 
site of carcinoma in Groups – II and III: 
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In Groups II and III oral carcinoma was seen in 6 different sites: 
tongue, buccal mucosa, alveolar mucosa, floor of the mouth, palate and both 
in tongue and floor of the mouth. 
          In Group II among the 20 subjects, 5(25%) had carcinoma in the 
tongue, 8(40%) had in the buccal mucosa, 3(15%) had in the alveolar 
mucosa, 2(10%) had carcinoma in the floor of the mouth and 1(5%) in the 
palate and 1(5%) in both the tongue and the floor of the mouth. 
          In Group III among the 20 subjects, 6(30%) had carcinoma in the 
tongue, 9(45%) had in the buccal mucosa, 4(20%) had in the alveolar 
mucosa, none had carcinoma in the floor of the mouth and in the palate and 
1(5%) had in both the tongue and the floor of the mouth. 
          In total among the 40 (100%), 11(27.5%) had carcinoma in the 
tongue, 17(42.5%) had in the buccal mucosa, 7(17.5%) had in the alveolar 
mucosa, 2(5%) had carcinoma in the floor of the mouth and 1(2.5%) in the 
palate and 2(5%) had in both the tongue and the floor of the mouth.The 
distribution of subjects according to the carcinoma site were found to be 
statistically non significant, with p-value 0.655. 
Table 8 and Graph 8 show the Salivary IgA levels in Groups I, II, III 
and IV: 
The maximum value for group I was 361.30 3µg/mL and the 
minimum value was 108.70 3µg/mL, in group II the maximum value was 
380.30 3µg/mL and the minimum value was 124.403µg/mL, in group III 
98.30 3µg/mL was the maximum value and 62.30 3µg/mL was the 
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minimum value and in group IV the maximum value was 109.20 3µg/mL 
and the minimum value was 32.60 3µg/mL.   
Mean Salivary IgA was highest in patients with oral carcinoma 
(Group II) (253.35 ± 83.3µg/mL) followed by patients with potentially 
malignant disorders (Group I) (201.7 ± 76.01 µg/mL), then patients with 
treated oral carcinoma (Group III) (76.26 ± 9.20 µg/mL) and lowest in 
controls (Group IV) (72.87 ± 26.46 µg/mL).  Comparison of these mean 
values by One-way ANOVA showed that there was a difference in mean 
values among the four study groups, with p-value 0.000 which is 
significant.   
Table 9 and Graph 9 show the Salivary IgG levels in Groups I, II, III 
and IV: 
The maximum value for group I was 15.80 mg/dL and the minimum 
value was 1.30 mg/dL, in group II the maximum value was 68.30 mg/dL 
and the minimum value was 11.0 mg/dL, in group III 25.40 mg/dL was the 
maximum value and 13.80 mg/dL was the minimum value and in group IV 
the maximum value was 27.0 mg/dL and the minimum value was 1.3mg/dL.   
Mean Salivary IgG was highest in patients with oral carcinoma 
(Group II) (33.86 ± 20.31mg/dL) followed by patients with treated oral 
carcinoma (Group III) (17.74 ± 3.12 µg/dL), then patients with potentially 
malignant disorders (Group I) (8.7± 4.07 µg/dL) and lowest in controls 
(Group IV) (6.58 ± 5.60 µg/dL).  Comparison of these mean values by One-
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way ANOVA showed that there was significant difference in mean values 
among the four study groups, with p-value 0.000 which is significant. 
Table 10 and Graph10 show the Salivary CRP levels in Groups I, II, III 
and IV: 
The maximum value for group I was 0.1 mg/L and the minimum 
value was 0.0 mg/L, in group II the maximum value was 0.4 mg/L and the 
minimum value was 0.0 mg/L, in group III 0.4 mg/L was the maximum 
value and 0.0 mg/L was the minimum value and in group IV the maximum 
value was 0.5 mg/L and the minimum value was 0.0 mg/L.                  
Mean Salivary CRP was highest in patients with treated oral 
carcinoma (Group III) (0.120 ± 0.128mg/L) followed by controls (0.070 ± 
0.13 mg/L), then patients with oral carcinoma (Group II) (0.050 ± 0.10 
mg/L) and lowest in patients with potentially malignant disorders (Group I) 
(0.015± 0.036 µg/mL).  Comparison of these mean values by One-way 
ANOVA showed that there was significant difference in mean values among 
the four study groups, with p-value 0.021 which is significant.    
Table 11 and Graph 11 show the Salivary Haptoglobin levels in Groups 
I, II, III and IV: 
The maximum value for group I was 3.80 mg/dL and the minimum 
value was 0.6 mg/dL, in group II the maximum value was 7.4 mg/dL and 
the minimum value was 3.1 mg/dL, in group III 2.0mg/dL was the 
maximum value and 0.4 mg/dL was the minimum value and in group IV the 
maximum value was 4.0 mg/dL and the minimum value was 0.8 mg/dL.   
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Mean Salivary Haptoglobin was highest in patients with oral 
carcinoma (Group II) (4.56 ± 1.19mg/dL) followed by controls (Group IV) 
(1.91 ± 0.895 mg/dL), then patients with potentially malignant disorders 
(Group I) (1.43 ± 0.843 mg/dL) and lowest in patients with treated oral 
carcinoma (Group III) (1.285 ± 0.492 mg/dL).  Comparison of these mean 
values by One-way ANOVA showed that there was significant difference in 
mean values among the four study groups, with p-value 0.000 which is 
significant.    
Table 12 and Graph 12 show the comparision of Salivary IgA levels in 
Group I with Groups II, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgA levels between Group I and Group II of (-51.6 ± 18.4) with p-
value of 0.031 that is statistically significant. There is a significant 
difference in the mean salivary IgA levels between Group I and Group III of  
(125.4 ± 18.4) with p-value of 0.000. The mean difference in the Salivary 
IgA levels between Group I and IV is (128.8 ± 18.4) that is statistically 
significant with a p-value of 0.000. 
Table 13 and Graph 13 show the comparison of the Salivary IgA levels 
in Group II with Groups I, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgA levels between Group II and Group I of (51.6 ± 18.4) with p-
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value of 0.031 that is statistically significant. There is a significant 
difference in the mean salivary IgA levels between Group II and Group III 
of (177.1 ± 18.4) with p-value of 0.000. The mean difference in the Salivary 
IgA levels between Group II and IV is (180.5 ± 18.4) that is statistically 
significant with a p-value of 0.000. 
Table 14 and Graph 14 show the comparison of Salivary IgA levels in 
Group III with Groups I, II and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgA levels between Group III and Group I of (125.4 ± 18.4) with p-
value of 0.000 that is statistically significant. There is a significant 
difference in the mean salivary IgA levels between Group III and Group II 
of (-177.1 ± 18.4) with p-value of 0.000. The mean difference in the 
Salivary IgA levels between Group III and IV is (3.4 ± 18.4) that is 
statistically not significant with a p-value of 0.998. 
Table 15 and Graph 15 show the comparison of the Salivary IgA levels 
in Group IV with Groups I, II and III: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgA levels between Group IV and Group I of (-128.8 ± 18.4) with 
p-value of 0.000 that is statistically significant. There is a significant 
difference in the mean salivary IgA levels between Group IV and Group II 
of (-180.5 ± 18.4) with p-value of 0.000. The mean difference in the 
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Salivary IgA levels between Group IV and III is (-3.4 ± 18.4) that is 
statistically not significant with a p-value of 0.998. 
Table 16 and Graph 16 show the comparison of Salivary IgG levels in 
Group I with Groups II, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgG levels between Group I and Group II of (-25.16 ± 3.43) with p-
value of 0.000 that is statistically significant. There is a significant 
difference in the mean salivary IgG levels between Group I and Group III of 
(-9.04 ± 3.43) with p-value of 0.049. The mean difference in the Salivary 
IgG levels between Group I and IV is (2.11 ± 3.43) that is statistically not 
significant with a p-value of 0.927. 
Table 17 and Graph 17 show the comparison of Salivary IgG levels in 
Group II with Groups I, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgG levels between Group II and Group I of (25.16 ± 3.43) with p-
value of 0.000 that is statistically significant. There is a significant 
difference in the mean salivary IgG levels between Group II and Group III 
of (16.1 ± 3.43) with p-value of 0.000. The mean difference in the Salivary 
IgG levels between Group II and IV is (27.2 ± 3.43) that is statistically 
significant with a p-value of 0.000. 
 
 
Results  
  
75 
 
 
Table 18 and Graph 18 show the comparison of Salivary IgG in Group 
III with Groups I, II and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgG levels between Group III and Group I of (9.04 ± 3.43) with p-
value of 0.049 that is statistically significant.  
There is a significant difference in the mean salivary IgG levels 
between Group III and Group II of (-16.1 ± 3.43) with p-value of 0.000. The 
mean difference in the Salivary IgG levels between Group III and IV is 
(11.1 ± 3.43) that is statistically significant with a p-value of 0.009. 
Table 19 and Graph 19 show the comparison of Salivary IgG in Group 
IV with Groups I, II and III: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary IgG levels between Group IV and Group I of (-2.1 ± 3.43) with p-
value of 0.927 that is statistically not significant. There is a significant 
difference in the mean salivary IgG levels between Group IV and Group II 
of (-27.2 ± 3.43) with p-value of 0.000. The mean difference in the Salivary 
IgG levels between Group IV and III is (-11.1 ± 3.43) that is statistically 
significant with a p-value of 0.009. 
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Table 20 and Graph 20 show the comparison of Salivary CRP levels in 
Group I with Groups II, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that the mean difference in the 
Salivary CRP  levels between Group I and Group II of  (-0.35 ± 0.033) with 
p-value of 0.723 that is statistically not significant. There is a significant 
difference in the mean salivary CRP  levels between Group I and Group III 
of (-1.050 ± 0.033) with p-value of 0.013. The mean difference in the 
Salivary CRP levels between Group I and IV is (-0.055 ± 0.033) that is 
statistically not significant with a p-value of 0.360. 
Table 21 and Graph 21 show the comparison of Salivary CRP levels in 
Group II with Groups I, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed the mean difference in the Salivary 
CRP levels between Group II and Group I of (0.035 ± 0.033) with p-value 
of 0.723 that is statistically not significant. The mean difference in the 
salivary CRP levels between Group II and Group III is (-0.070 ± 0.033) with 
p-value of 0.164 that is statistically not significant. The mean difference in 
the Salivary CRP levels between Group II and IV is (-0.020 ± 0.033) that is 
statistically not significant with a p-value of 0.932. 
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Table 22 and Graph 22 show the comparison of Salivary CRP in Group 
III with Groups I, II and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean                                    
difference in the Salivary CRP levels between Group III and Group I of (-
1.050 ± 0.033) with p-value of 0.013 that is statistically significant. The 
mean difference in the salivary CRP levels between Group III and Group II 
is (-0.070 ± 0.033) with p-value of 0.164 which is statistically not 
significant. The mean difference in the Salivary CRP levels between Group 
III and IV is (0.050 ± 0.033) that is statistically not significant with a               
p-value of 0.445. 
Table 23 and Graph 23 show the comparison of Salivary CRP in Group 
IV with Groups I, II and III: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed the mean difference in the Salivary 
CRP levels between Group IV and Group I of (0.055 ± 0.033) with p-value 
of 0.360 that is statistically not significant. The mean difference in the 
salivary CRP levels between Group IV and Group II is (0.020 ± 0.033) with 
p-value of 0.932. The mean difference in the Salivary CRP levels between 
Group IV and III is (0,050 ± 0.033) that is statistically not significant with a 
p-value of 0.445. 
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Table 24 and Graph 24 show the comparison of Salivary Haptoglobin 
levels in Group I with Groups II, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean  
difference in the Salivary Haptoglobin levels between Group I and Group II 
of (-3.135 ± 0.282) with p-value of 0.000 that is statistically significant. The 
mean difference in the salivary Haptoglobin levels between Group I and 
Group III is (0.145 ± 0.282) with p-value of 0.955 which is statistically not 
significant. The mean difference in the Salivary Haptoglobin levels between 
Group I and IV is (-0.48 ± 0.282) that is statistically not significant with a  
p-value of 0.329. 
Table 25 and Graph 25 show the comparison of Salivary Haptoglobin 
levels in Group II with Groups I, III and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed that there is a mean difference in the 
Salivary Haptoglobin levels between Group II and Group I of (3.135 ± 
0.282) with p-value of 0.000 that is statistically significant. There is a 
significant difference in the mean salivary Haptoglobin levels between 
Group II and Group III of (3.28 ± 0.282) with p-value of 0.000. The mean 
difference in the Salivary Haptoglobin levels between Group II and IV is 
(2.65 ± 0.282) that is statistically significant with a p-value of 0.000. 
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Table 26 and Graph 26 show the comparison of Salivary Haptoglobin in 
Group III with Groups I, II and IV: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed the mean difference in the Salivary 
Haptoglobin levels between Group III and Group I of (-0.145 ± 0.282) with 
p-value of 0.955 that is statistically not significant. There is a significant 
difference in the mean salivary Haptoglobin levels between Group III and 
Group II of (-3.28 ± 0.282) with p-value of 0.000. The mean difference in 
the Salivary Haptoglobin levels between Group III and IV is (-0.625 ± 
0.282) that is statistically not significant with a p-value of 0.128. 
Table 27 and Graph 27 show the comparison of Salivary Haptoglobin in 
Group IV with Groups I, II and III: 
The comparison between the groups had been done by following 
Tukey HSD procedure which showed the mean difference in the Salivary 
Haptoglobin levels between Group IV and Group I of (0.48 ± 0.282) with p-
value of 0.329 that is statistically not significant. There is a significant 
difference in the mean salivary Haptoglobin levels between Group IV and 
Group II of (-2.655 ± 0.282) with p-value of 0.000. The mean difference in 
the Salivary Haptoglobin levels between Group IV and III is (0.625 ± 0.282) 
that is statistically not significant with a p-value of 0.128. 
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TABLE – I: DISTRIBUTION OF SUBJECTS BY SEX 
 
 
SEX 
GROUP I 
(Potentially 
malignant 
disorders) 
GROUP II 
(Untreated 
oral 
carcinoma) 
GROUP 
III 
( Treated 
oral 
carcinoma)
GROUP 
IV 
(Controls)
 
 
TOTAL 
 
MALE 
 
18 
 
90% 
 
15
 
75% 
 
14
 
60% 
 
15
 
75% 
 
62 
 
77.5% 
 
FEMALE 
 
2 
 
10% 
 
5 
 
25% 
 
6 
 
40% 
 
5 
 
25% 
 
18 
 
22.5% 
 
TOTAL 
 
20 
 
100% 
 
20
 
100% 
 
20
 
100% 
 
20
 
100%
 
80 
 
100% 
           P-value: 0.46 (not significant) 
 
TABLE – II: DISTRIBUTION OF SUBJECTS BY AGE 
 
AGE 
(Years) 
GROUP I 
(Potentially 
malignant 
disorders) 
GROUP II 
( Untreated 
oral 
carcinoma) 
GROUP III
( Treated 
oral 
carcinoma) 
GROUP 
IV 
(Controls) 
 
TOTAL 
 
15-25 
 
5 
 
25% 
 
0 
 
0% 
 
1 
 
5% 
 
3 
 
15% 
 
9 
 
11.25% 
 
26 – 35 
 
4 
 
20% 
 
2 
 
10% 
 
3 
 
15% 
 
5 
 
25% 
 
14 
 
17.5% 
 
36 – 45 
 
5 
 
25% 
 
8 
 
40% 
 
7 
 
35% 
 
6 
 
30% 
 
26 
 
32.5% 
 
46 – 55  
 
2 
 
10% 
 
4 
 
20% 
 
4 
 
20% 
 
2 
 
10% 
 
12 
 
15% 
 
56 – 65 
 
1 
 
5% 
 
5 
 
25% 
 
3 
 
15% 
 
3 
 
15% 
 
12 
 
15% 
 
>65 
 
3 
 
15% 
 
1 
 
5% 
 
2 
 
10% 
 
1 
 
5% 
 
7 
 
8.75% 
 
TOTAL 
 
20 
 
100% 
 
20 
 
100% 
 
20 
 
100% 
 
20
 
100% 
 
80 
 
 
 
100% 
          P-value: 0.111(not significant) 
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TABLE – III: DISTRIBUTION OF SUBJECTS BASED ON HABITS 
 
 
 
 
HABIT/ 
GROUP 
 
 
No habits 
 
 
Smoking 
 
 
 
Chewing 
 
 
Chewing 
+ 
Smoking 
 
Smoking 
+ 
Alcohol 
 
 
Chewing 
+ 
Alcohol 
 
Chewing 
+ 
Smoking 
+ 
Alcohol 
 
 
Total 
 
Group I 0 0% 4 20% 8 40% 4 20% 3 15% 1 5% 0 0% 20 100% 
Group II 0 0% 5 25% 7 35% 3 15% 3 15% 0 0% 2 10% 20 100% 
Group III 0 0% 6 30% 6 30% 4 20% 3 15% 0 0% 1 5% 20 100% 
Group 
IV 11 55% 5 25% 2 10% 1 % 1 5% 0 0% 0 0% 20 100% 
Total 1 13.8% 20 25% 23 28.8% 12 15% 10 12.5% 1 1.3% 3 3.8% 80 100% 
 
P-value: 0.000 (significant) 
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TABLE – IV DISTRIBUTION OF SUBJECTS ACCORDING TO 
LESION 
 
 
 
 
 
GROUP – I 
 
TOTAL 
 
 
LESION 
 
OSMF 
 
9 
 
45% 
 
9 
 
45% 
 
LEUKOPLAKIA 
 
11 
 
55% 
 
11 
 
55% 
 
TOTAL 
 
20 
 
100% 
 
20 
 
100% 
 
 
TABLE – V DISTRIBUTION OF SUBJECTS ACCORDING TO THE 
SITE OF LEUKOPLAKIA 
 
  
GROUP – I 
 
TOTAL 
 
 
 
 
LEUKOPLAKIA 
SITE 
RETRO 
COMMISSURE 
AREA 
 
7 
 
63.6% 
 
7 
 
63.6% 
BUCCAL 
MUCOSA 
 
2 
 
18.2% 
 
2 
 
18.2% 
FLOOR OF 
THE MOUTH 
 
1 
 
9.1% 
 
1 
 
9.1% 
 
TONGUE 
 
1 
 
9.1% 
 
1 
 
9.1% 
 
TOTAL 
 
11 
 
100% 
 
11 
 
100% 
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TABLE – VI DISTRIBUTION OF SUBJECTS ACCORDING TO THE 
GRADE OF ORAL SUBMUCOUS FIBROSIS 
 
 GROUP – I TOTAL 
 
 
 
 
OSMF 
GRADE 
 
GRADE I 
 
2 
 
22.2% 
 
2 
 
22.2% 
 
GRADE II 
 
0 
 
0% 
 
0 
 
0% 
 
GRADE III 
 
5 
 
55.6% 
 
5 
 
55.6% 
 
GRADE IV 
 
 
2 
 
22.2% 
 
2 
 
22.2% 
 
TOTAL 
 
9 
 
100% 
 
9 
 
100% 
 
TABLE – VII DISTRIBUTION OF SUBJECTS ACCORDING TO THE 
SITE OF CARCINOMA 
 
 
GROUPS 
 
TOTAL GROUP – 
II 
GROUP – 
III 
 
 
 
 
 
CARCINOMA 
SITE 
TONGUE 5 25% 6 30% 11 7.5% 
BUCCAL 
MUCOSA 8 40% 9 45% 17 42.5% 
ALVEOLAR 
MUCOSA 3 15% 4 20% 7 17.5% 
FLOOR OF 
THE MOUTH 2 10% 0 0% 2 5% 
 
PALATE 1 5% 0 0% 1 2.5% 
TONGUE + 
FLOOR OF 
THE MOUTH 
1 5% 1 5% 2 5% 
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TOTAL 20 100% 20 100% 40 100% 
   P-Value: 0.655 (not significant) 
TABLE – VIII  SALIVARY IgA LEVELS IN GROUP I, II, III AND IV 
 
S.NO 
GROUP – I 
µg/mL 
GROUP – II 
µg/mL 
GROUP – 
III 
µg/mL 
GROUP – 
IV 
µg/mL 
1 
 132.92 141.44 67.45 88.21 
2 
 156.24 125.71 82.0 107 
3 
 287.8 338.98 62.3 109.2 
4 
 317.10 380.34 73.4 47.6 
5 
 113.76 273.73 66.0 43.7 
6 
 150.84 124.42 72.65 33.3 
7 
 142.63 139.23 79.78 79 
8 
 243.69 268.23 64.5 40.3 
9 
 133.9 246.09 79.8 32.6 
10 
 161.55 330.23 68.4 43.3 
11 
 180.6 208.66 78.4 40.6 
12 
 113.17 237.33 89.0 83.6 
13 
 230.74 250.42 98.3 103 
14 
 237.13 273.08 83.7 82.7 
15 
 241.6 356.07 79.2 74.84 
16 
 108.79 365.78 77.8 103.85 
17 
 161 295.74 75.28 87.78 
18 296.6 153.45 87.8 81.67 
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19 
 361.37 234.46 72.8 81.2 
20 262.8 324.64 67 94.24 
          P-Value: 0.000 (significant) 
TABLE – IX SALIVARY IgG LEVELS IN GROUP I, II, III AND IV 
 
S.NO 
GROUP – I 
mg/dL 
GROUP – II 
mg/dL 
GROUP – 
III 
mg/dL 
GROUP – 
IV 
mg/dL 
1 
 7.6 22 25.4 27.9 
2 
 1.3 15.2 16.7 4.8 
3 
 14.7 20 15.4 6.0 
4 
 13.0 11 18.5 8.2 
5 
 5.5 29 16 5.5 
6 
 15.8 55.8 25.0 5.4 
7 
 15.0 12.0 16.5 6.7 
8 
 5.3 14.2 17.5 5.6 
9 
 6.9 23.3 14.6 6.5 
10 
 15.3 18.8 13.8 3.4 
11 
 9.6 4.1 17.4 3.7 
12 
 6.4 53.4 17.57 1.5 
13 
 5.5 57.0 18.4 3.8 
14 
 5.3 68.3 21.30 5.5 
15 
 9.2 55.0 20.2 10.3 
16 
 9.2 48.6 15.0 2.8 
17 
 5.9 52.3 17.6 7.2 
18 8.1 66 15.0 1.3 
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19 
 8.9 14.5 16.3 3.0 
20 5.5 25.7 16.7 13.5 
      P-Value: 0.000(significant) 
TABLE – X SALIVARY CRP LEVELS IN GROUP I, II, III AND IV 
 
S.NO 
GROUP – I 
mg/L 
GROUP – II 
mg/L 
GROUP – 
III 
mg/L 
GROUP – 
IV 
mg/L 
1 
 0.1 0.1 0 0.5 
2 
 0 0 0 0 
3 
 0 0 0.1 0.1 
4 
 0 0 0.1 0.1 
5 
 0 0.2 0.4 0 
6 
 0 0.1 0.2 0.1 
7 
 0 0 0.1 0 
8 
 0 0 0 0 
9 
 0 0 0 0 
10 
 0 0 0.2 0 
11 
 0 0 0.1 0 
12 
 0 0 0.1 0.3 
13 
 0 0 0.4 0 
14 
 0 0 0.2 0.2 
15 
 0 0.4 0.1 0 
16 
 0 0.1 0 0 
17 
 0 0 0 0 
18 0.1 0 0.1 0 
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19 
 0 0.1 0.3 0.1 
20 0.1 0 0 0 
  P-Value:0.021(significant) 
TABLE-XI SALIVARY HAPTOGLOBIN LEVELS IN GROUP I, II, III &  IV 
 
S.NO 
GROUP – I 
mg/dL 
GROUP – II 
mg/dL 
GROUP – 
III 
mg/dL 
GROUP – 
IV 
mg/dL 
1 
 
1.1 6.2 1.4 0.8 
2 
 
2.8 3.7 2.2 1.7 
3 
 
2.4 3.5 1.5 2.0 
4 
 
3.8 3.5 0.4 1.2 
5 
 
1.6 3.1 0.7 1.3 
6 
 
2.4 5.0 1.8 2.2 
7 
 
1.8 3.3 2 1.5 
8 
 
0.6 4.4 1.4 1.0 
9 
 
0.7 4.1 0.8 1.3 
10 
 
1.2 5.5 0.5 2.2 
11 
 
1.0 3.9 1.7 2.7 
12 
 
1.2 4.1 1.5 1.7 
13 
 
0.7 3.6 1.0 0.9 
14 
 
0.9 7.4 1.8 4 
15 
 
0.7 6.3 1.3 3.3 
16 
 
0.8 5.8 1.6 3.5 
17 
 
0.8 3.7 1.4 1.0 
18 1.1 5.5 1.8 1.9 
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19 
 
1.7 3.9 1.5 1.7 
20 1.3 4.8 0.4 2.3 
      P-Value: 0.000(significant) 
TABLE – XII COMPARISON OF SALIVARY IgA LEVELS OF 
GROUP – I WITH GROUPS – II, III AND IV 
 
 
GROUP 
 
COMPARISON
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P - 
VALUE 
 
 
 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
GROUP – II 
ORAL 
CARCINOMA
 
-51.6 
 
18.4 
 
0.031 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA
 
125.4 
 
18.4 
 
0.000 
 
GROUP – IV 
CONTROLS 
 
128.8 
 
18.4 
 
0.000 
 
TABLE – XIII COMPARISON OF SALIVARY IgA LEVELS OF 
GROUP – II WITH GROUPS – I, III AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – II 
ORAL 
CARCINOMA 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
51.6 
 
18.4 
 
0.031 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
177.1 
 
18.4 
 
0.000 
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GROUP – IV 
CONTROLS 
 
180.5 
 
18.4 
 
0.000 
TABLE – XIV COMPARISON OF SALIVARY IgA LEVELS OF 
GROUP – III WITH GROUPS – I, II AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
125.4 
 
18.4 
 
0.000 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-177.1 
 
18.4 
 
0.000 
 
GROUP – IV 
CONTROLS 
 
3.4 
 
18.4 
 
0.998 
 
 
TABLE – XV COMPARISON OF SALIVARY IgA LEVELS OF 
GROUP – IV WITH GROUPS – I, II AND III 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – 
IV 
CONTROLS 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
-128.8 
 
18.4 
 
0.000 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-180.5 
 
18.4 
 
0.000 
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GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
-3.4 
 
18.4 
 
0.998 
 
TABLE – XVI COMPARISON OF SALIVARY IgG LEVELS OF 
GROUP – I WITH GROUPS – II, III AND IV 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P - 
VALUE 
 
 
 
 
GROUP – I 
POTENTIALLY  
MALIGNANT 
DISORDERS 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-25.16 
 
3.43 
 
0.000 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
-9.04 
 
 
3.43 
 
0.049 
 
 
GROUP – IV 
CONTROLS 
 
2.11 
 
3.43 
 
0.927 
 
TABLE – XVII COMPARISON OF SALIVARY IgG LEVELS OF 
GROUP – II WITH GROUPS – I, III AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – II 
ORAL 
CARCINOMA 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
25.16 
 
3.43 
 
0.000 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
16.1 
 
 
3.43 
 
0.000 
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GROUP – IV 
CONTROLS 
 
27.2 
 
 
3.43 
 
 
0.000 
 
 
TABLE – XVIII COMPARISON OF SALIVARY IgG LEVELS OF 
GROUP – III WITH GROUPS – I, II AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
9.04 
 
3.43 
 
0.049 
 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-16.1 
 
 
 
3.43 
 
0.000 
 
GROUP – IV 
CONTROLS 
 
11.1 
 
 
3.43 
 
0.009 
 
 
 
TABLE – XIX COMPARISON OF SALIVARY IgG LEVELS OF 
GROUP – IV WITH GROUPS – I, II AND III  
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – VALUE 
 
 
 
 
 
 
GROUP – 
IV 
CONTROLS 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
-2.1 
 
3.43 
 
0,927 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-27.2 
 
3.43 
 
0.000 
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GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
-11.1 
 
3.43 
 
0.009 
 
 
TABLE – XX COMPARISON OF SALIVARY CRP LEVELS OF 
GROUP – I WITH GROUPS – II, III AND IV 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P - 
VALUE 
 
 
 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-0.35 
 
0.033 
 
0.723 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
-1.050 
 
0.033 
 
0.013 
 
GROUP – IV 
CONTROLS 
 
-0.055 
 
0.033 
 
0.360 
 
 
TABLE – XXI COMPARISON OF SALIVARY CRP LEVELS OF 
GROUP – II WITH GROUPS – I, III AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – II 
ORAL 
CARCINOMA 
 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
0.035 
 
0.033 
 
0.723 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
-0.070 
 
0.033 
 
0.164 
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GROUP – IV 
CONTROLS 
 
-0.020 
 
0.033 
 
0.932 
 
TABLE – XXII COMPARISON OF SALIVARY CRP LEVELS OF 
GROUP – III WITH GROUPS – I, II AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
-1.050 
 
0.033 
 
0.013 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-0.070 
 
0.033 
 
0.164 
 
GROUP – IV 
CONTROLS 
 
0.050 
 
0.033 
 
0.445 
 
 
TABLE – XXIII COMPARISON OF SALIVARY CRP LEVELS OF 
GROUP – IV WITH GROUPS – I, II AND III 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – 
IV 
CONTROLS 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS 
 
0.055 
 
0.033 
 
0.360 
 
GROUP – II 
ORAL 
CARCINOMA 
 
0.020 
 
0.033 
 
0.932 
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GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
0.050 
 
0.033 
 
0.445 
 
TABLE – XXIV COMPARISON OF SALIVARY HAPTOGLOBIN 
LEVELS OF GROUP – I WITH GROUPS – II, III AND IV 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P - 
VALUE 
 
 
 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-3.135 
 
0.282 
 
0.000 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
0.145 
 
0.282 
 
0.955 
 
GROUP – IV 
CONTROLS 
 
-0.48 
 
0.282 
 
0.329 
 
 
 
TABLE – XXV COMPARISON OF SALIVARY HAPTOGLOBIN 
LEVELS OF GROUP – II WITH GROUPS – I, III AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – II 
ORAL 
CARCINOMA 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
3.135 
 
0.282 
 
0.000 
 
GROUP – III 
TREATED 
ORAL 
 
3.28 
 
0.282 
 
0.000 
 
 
 
Tables & Graphs 
 
96 
 
 CARCINOMA 
 
GROUP – IV 
CONTROLS 
 
2.65 
 
0.282 
 
0.000 
TABLE – XXVI COMPARISON OF SALIVARY HAPTOGLOBIN 
LEVELS OF GROUP – III WITH GROUPS – I, II AND IV 
 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
 
 
GROUP – I 
POTENTIALLY
MALIGNANT 
DISORDERS
 
-0.145 
 
0.282 
 
0.955 
 
GROUP – II 
ORAL 
CARCINOMA 
 
-3.28 
 
0.282 
 
0.000 
 
GROUP – IV 
CONTROLS 
 
-0.625 
 
0.282 
 
0.128 
 
 
 
TABLE – XXVII COMPARISON OF SALIVARY HAPTOGLOBIN 
LEVELS OF GROUP – IV WITH GROUPS – I, II AND III 
 
 
GROUP 
 
COMPARISON 
GROUPS 
 
MEAN 
DIFFERENCE 
 
STANDARD 
ERROR 
 
P – 
VALUE 
 
 
 
 
 
 
GROUP – IV 
CONTROLS 
 
GROUP – I 
POTENTIALLY 
MALIGNANT 
DISORDERS 
 
0.48 
 
0.282 
 
0.329 
 
GROUP – II 
ORAL 
 
-2.655 
 
0.282 
 
0.000 
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 CARCINOMA 
 
GROUP – III 
TREATED 
ORAL 
CARCINOMA 
 
0.625 
 
0.282 
 
0.128 
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Oral cancer is one of the most deadly forms of cancer is the 6th 
commonest form of cancer worldwide. In India, it the most common type of 
cancer. Oral cancer is strongly associated with certain environmental and 
lifestyle risk factors, including tobacco, smoking, alcohol consumption, UV 
light and occupational exposures, and certain strains of viruses, such as the 
sexually transmitted human papilloma virus. These cancers are frequently 
aggressive in their biologic behaviour; patients with these types of cancer 
often develop a second primary tumour.46 
The absence of definite early warning signs for most head and neck 
cancers suggests that sensitive and specific biomarkers are likely to be 
important in screening high-risk patients. Salivary analysis holds promise as 
a non-invasive approach to identify biomarkers for human oral cancer.18, 36 
Salivary immunoglobulins play a role in host anti-tumor surveillance 
mechanisms. The predominant immunoglobulin in saliva is IgA. 
Approximately 90% of IgA in saliva is present as secretory IgA (S-IgA). 
Secretary immunoglobulin G (S-IgG) is present in saliva in very low 
quantities.74 The Acute Phase Reactant Proteins (APRPs) are group of 
plasma proteins that alter their concentration in response to varied diseases. 
The levels of APRPs were shown to reflect events in tumour invasion and 
metastasis and were used in biochemical monitoring of cancer.44 
This study deals with the salivary analysis to evaluate the 
immunological parameters like IgA, IgG, C-reactive protein and 
haptoglobin in the saliva of patients with potentially malignant disorders, 
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oral squamous cell carcinoma (OSCC) and patients treated for oral 
squamous cell carcinoma. 
This study was conducted between April 2009 to May 2010 in the 
department of Oral Medicine and Radiology of Ragas Dental College and 
Hospital, Dr. Rai Memorial Medical and Cancer Centre, Chennai. 
A case control study was conducted in which 80 subjects were 
selected. The study subjects were categorized into three groups: Group I 
consist of 20 patients who were suffering from potentially malignant 
disorders like Leukoplakia and Oral submucous fibrosis; Group II, 20 
patients suffering from Oral cancer; Group III, 20 patients who were treated 
for oral cancer and Group IV, 20 normal controls. 
Participants with infectious diseases during one month before saliva 
sampling, active dental abscesses’, and collagen vascular diseases were 
excluded from the study. 
Among the 80 subjects 62(77.5%) were males and 18(22.5%) were 
females. The minimum age of the study subjects was 19 years and the 
maximum age was 75 years. 
In the present study, among the 80 subjects 20(25%) had the habit of 
smoking, 23(28.8%) had the habit of chewing, 12(15%) had the habit of 
chewing and smoking, 10(12.5%) had the habit of smoking and alcohol 
consumption,1(1.3%) had the habit of chewing and alcohol consumption 
and 3(3.8%) had all three habits together with a p-value of 0.000 which is 
statistically significant. Thus a positive correlation between smoking, 
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chewing, alcohol consumption and development of precancer and cancer has 
been established.  
This is in accordance with various similar studies. Pindborg et al in 
198459 performed a study on 100 subjects for their smoking and chewing 
habits and the condition of their oral mucosa. The predominant occurrence 
of oral submucous fibrosis was seen and the dominating habits were areca 
nut chewing and cigarette smoking and areca nut chewing and water pipe 
smoking in female population. Pindborg et al in 199760 examined 1866 
individuals and found a positive correlation between leukoedema, 
preleukoplakia and leukoplakia and the habit of smoking. Salonen et al in 
1990 68 reported a positive correlation between tobacco use and leukoplakia 
on his study on 920 individuals. Sankaranarayanan in 199069 found a causal 
association between oral cancer and the chewing of betel quid containing 
tobacco leaves or stem and other tobacco habits. Rajendran.R et at in 198662 
reviewed the etiology and pathogenesis of Oral submucous fibrosis. He 
suggested that certain customs or habits (chewing) prevalent among the 
population groups in South East Asia might be possible etiological factors. 
Shah N, Sharma PP in 199873 conducted a study to identify the role of 
chewing and smoking habit in the etiology of oral submucous fibrosis. In 
this study 236 cases of oral submucous fibrosis were compared with 221 
control subjects matched for age, sex and socioeconomic conditions. It was 
found that chewing of areca nut, quid and pan masala was directly related to 
oral submucous fibrosis and not a single case was found without any 
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chewing habit. Crispian Scully et al in 200018 stated that the etiological 
factors of oral cancer include tobacco use, betel use (Bidi leaf, and often 
tobacco, plus spices, slaked lime, and areca nut) and alcohol consumption. 
Zain et al in 200192 stated about the role of tobacco smoking, chewing of 
tobacco, areca nut, and betel quid and drinking of alcohol are established 
cultural risk factors of oral pre-cancer and oral cancer worldwide. 
Saraswathi et al in 200670 stated that the habit of smoking, drinking and 
chewing tobacco products were common oral habits in India and these 
habits were positively related with development of oral lesion such as 
OSMF, leukoplakia and oral lichen planus which had potential for 
malignant transformation. 
In the present study, the most common site for leukoplakia was in 
the retro-commissure area with 7(63.6%) subjects followed by buccal 
mucosa 2 (18.2%) and one each in the tongue and floor of the mouth. Jain et 
al in 199539 found that the most common site of leukoplakia was on the 
buccal mucosa 67.33% with p-value <0.01.   
The present study showed all cases of OSMF in the buccal mucosa, 
with 5 (55.6%) in Grade III and 2 each in Grades I and IV and none in 
Grade II. Shah et al (1998)73 stated that OSMF predominantly affects the 
buccal mucosa with the p-value <0.001.  
In the present study among the total of 40 (100%) subjects, 
11(27.5%) had carcinoma in the tongue, 17(42.5%) had in the buccal 
mucosa, 7(17.5%) had in the alveolar mucosa, 2(5%) had carcinoma in the 
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floor of the mouth and 1(2.5%) in the palate and 2(5%) had in both the 
tongue and the floor of the mouth. Oral cancer was mostly seen in the 
buccal mucosa, followed by tongue, alveolar mucosa, floor of the mouth and 
palate. Prabhu SR et al in 198861 found the most common site of oral cancer 
was buccal mucosa followed by tongue and other sites. Mehrota et al in 
200351 stated that oral cancer was the commonest malignancy in Allahabad 
and buccal mucosa was the most common site of oral cancer. 
Kayambe in 199943 performed a study in Congo and found palate to 
be the most frequent site and squamous cell carcinoma was most common 
type of cancer. This may be attributed to the different predominant habit of 
the subjects included in the study by Kayambe when compared to the 
subjects included in the present study and hence there is a different site 
predilection for oral carcinoma. 
In the present study elevated levels of salivary IgA, IgG and 
Haptoglobin were observed in patients with potentially malignant disorders 
like leukoplakia and oral submucous fibrosis with a p-value of 0.000 which 
is significant. The mean salivary IgA in patients with potentially malignant 
disorders was 201.7 ± 76.01 µg/mL, the mean salivary IgG was 8.7± 4.07 
µg/dL and the mean salivary haptoglobin was 1.43 ± 0.843 mg/dL. In 
controls the mean salivary IgA was 72.87 ± 26.46 µg/mL, the mean salivary 
IgG 6.58 ± 5.60 µg/dL and the mean salivary haptoglobin was 1.91 ± 0.895 
mg/dL. This is in accordance with the similar studies conducted by Phatak 
AG and Gosavi DK 197558 (p-value of <0.001) Thomas Loning 197981, 
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Rajendran 198662 (p-value <0.001) and Krasteva 200846 (IgA: p-value of 
0.043 and IgG: p-value of 0.018). Phatak AG and Gosavi DK in 197558 
reported that the total IgG was significantly elevated in OSMF patients 2009 
± 258mg/100mL when compared to that in controls 1708 ±  346mg/100mL 
with a p-value of <0.001. Thomas Loning et al in 197981 found that the 
incidence of immunoglobulins (IgA and IgG) was twice as high in those 
cases of leukoplakia where dysplasia was present but no numerical values 
were given. Rajendran et al in 198662 found a significant rise in IgA levels 
with p-value of <0.001 in patients with oral submucous fibrosis. Krasteva.A 
et al in 200846 found that salivary IgA and IgG were significantly increased 
in patients with precancerous lesions. The salivary IgA levels were 168mg/L 
when compared to the controls  83mg/L with p-value of 0.043 and salivary 
IgG levels were 70mg/L in precancerous lesions, in controls  22mg/L with 
p-value of 0.018. 
The present study showed that there was a significant rise in the 
salivary IgA, IgG, and Haptoglobin with a p-value of 0.000 and a slight 
elevation in the salivary CRP levels in patients with oral carcinoma with a 
p-value of 0.021 which is significant. The mean salivary IgA in patients 
with oral carcinoma was 253.35 ± 83.3µg/mL, the mean salivary IgG was 
33.86 ± 20.31mg/dL, mean salivary CRP was 0.050 ± 0.10 µg/mL and the 
mean salivary haptoglobin was 4.56 ± 1.19mg/dL. In controls the mean 
salivary IgA was 72.87 ± 26.46 µg/mL, the mean salivary IgG 6.58 ± 5.60 
µg/dL, the mean salivary CRP was 0.070 ± 0.13 mg/L and the mean salivary 
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haptoglobin was 1.91 ± 0.895 mg/dL. This is in accordance with similar 
studies by Mark.A 197349 (mean IgA: 2.15± 0.65mg with p-value <0.001), 
Ashley M. Brown 197504 (p-value-0.01), Rajendran 198662 (p-
value<0.0001), Hu-De-En 198738 (p-value<0.01), Gallo.O 199430 (IL-6 and 
CRP r = 0.69 with p-value of 0.0001), Dritan Turhani 200520, Kashmoola 
200142and Al-Rawi 200503,  Krasteva 200846 (IgA and IgG: p-value 0.000, 
CRP: p-value 0.004 and haptoglobin: p-value 0,006) and 
Sunil.D.Khandavilli 200980 (p = 0.003). Mark.A et al in 197349 found that 
the highest IgA titers were seen in patients with oral and pulmonary cancers 
with the mean IgA: 2.15± 0.65mg which was 3.5 times that of the control 
group with a p-value <0.001. Ashley M. Brown et al in 197504 stated that 
the IgA content of whole saliva of cancer patients was significantly elevated 
above that of controls. The elevation of saliva when compared to control 
patients was significant at the .01 level. Rajendran et al in 198662 found a 
significant rise in IgA levels with p-value of <0.0001 in oral cancer patients. 
He also stated that the immunological derangements were more pronounced 
in oral cancer than in OSMF. Hu – De – En et al in 198738 found that there 
was a tendency for higher levels of immunoglobulins to be associated with 
more advanced stage of carcinoma. The IgA levels were 295 ± 112mg% and 
IgG levels were 2076 ± 587mg% with p-value of <0.01. Gallo.O et al in 
199430 conducted a study in 18 patients with oral squamous cell carcinoma 
and found an increase in IL-6 which in turn induces the synthesis of CRP in 
head and neck carcinoma. Significant (P < 0.0001) relationships were found 
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between IL-6 and CRP (r = 0.69). Dritan Turhani et al in 200520  has 
demonstrated an increase in the levels of CRP in oral squamous cell 
carcinoma patients. Kashmoola et al in 200142 and Al-Rawi et al in 200503 
had showed that patients with oral squamous cell carcinoma had markedly 
increased salivary total protein concentration which may be due to 
increasing salivary immunoglobulins. Numerical values were not given for 
discussion. Krasteva.A et al in 200846 found that the salivary levels of IgA, 
IgG, CRP and Haptoglobin in patients with oral carcinoma were 
significantly increased. Salivary IgA levels were 152mg/L with p-value 
0.000, Salivary IgG levels were 38mg/L p-value 0.000, CRP levels were 
0.157mg/L p-value 0.004 and Haptoglobin levels were 30 with p-value 
0.006. Sunil.D. Khandavilli et al in 200980 did a study which was designed 
to establish if elevated preoperative levels of CRP could predict the 
prognosis of patients treated with primary surgery for oral squamous cell 
carcinoma (SCC). He stated that a raised preoperative CRP with p-value of 
0.003 was associated with worse overall survival. 
          The studies by Thomas Loning 197981, Robino Muchado de Souza 
200367 (salivary IgA : 13.7± 3.9 mg/dL) and Shpitzer.T 200774 (salivary IgG 
125%, P = 0.01, while S-IgA was lower by 45% P = 0.001) are not in 
accordance with the present study. Thomas Loning et al in 197981 found that 
the concentration of IgA and IgG decreased significantly with tumor 
dedifferentiation. Robino Muchado de Souza et al in 200367 found that 
salivary IgA levels were reduced in cancer patients and were related to 
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malnutrition, stress and tobacco. He found that the mean salivary IgA level 
was 17.0 ± 10.4mg/dL in controls and 13.7± 3.9 mg/dL in oral cancer 
patients. Shpitzer.T et al in 200774 utilized comprehensive salivary analysis 
to evaluate biochemical and immunological parameters in the saliva of oral 
squamous cell carcinoma patients. He found that the concentration of 
salivary IgG was higher by 125% in oral squamous cell carcinoma patients 
while the concentration of secretory IgA was lowered by 45%. This may be 
attributed to the small sample size in the present study, the age of the 
patients and the immune status of the patients. 
In the present study the salivary IgA, IgG and CRP in treated oral 
cancer patients remained significantly higher with a p-value of 0.000 which 
is significant. The mean salivary IgA in patients with treated oral carcinoma 
was 76.26 ± 9.20 µg/mL, the mean salivary IgG was 17.74 ± 3.12 µg/dL and 
the mean salivary CRP was 0.120 ± 0.128mg/L. In controls the mean 
salivary IgA was 72.87 ± 26.46 µg/mL, the mean salivary IgG 6.58 ± 5.60 
µg/dL and the mean salivary CRP was 0.070 ± 0.13 mg/L. This is in 
accordance with similar studies by Einhorn 197222(p-value <0.01) Brown 
198111 (p<0.03)  Jankovic 199540 (mean salivary IgG :0.095 g/l) and 
Krasteva.A 200846 (p<0.05). Einhorn et al in 197222 observed elevated 
levels of IgG at the time of completion of radiotherapy and higher levels 3 
months after radiotherapy. This may represent enhanced immunization by 
antigens released during radiation induced tumour breakdown. Brown et al 
in 198111 found that following radiotherapy changes in specific 
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agglutination titers of oral isolates reflected changes in saliva IgA. He found 
13 patients with increased salivary IgA with p-value of <0.03 when he 
assessed 36 patients over a 30 month post-irradiation period. Jankovic.L et 
al in 199540 in his study on 40 patients with neoplastic disorders who have 
been treated has found that the mean IgG/IgA salivary ratio was 1.27 
(normally below 1.0) due to an increased salivary concentration of IgG 
(mean 0.095 g/l). Krasteva.A et al in 200846 found that the salivary levels of 
IgG and IgA remain significantly higher (p<0.05) in treated cancer patients.  
          The studies conducted by Thomas Loning 197981, Hu-De-En 198738 
(p-value of <0.01) and Meurman JH 199753 (p-value<0.001) were not in 
accordance with the present study. Thomas Loning et al in 197981 found that 
the immunoglobulins (IgA and IgG) levels decreased after radiation therapy. 
Hu De-En et al in 198738 reported that the levels of IgG decreased markedly 
after radiation therapy. IgG levels were 2076 ± 567 mg% in oral cancer 
patients and in patients treated with radiotherapy the IgG levels decreased 
1901 ± 688mg% with a p-value of <0.01. Meurman JH et al in 199753 found 
that the total salivary IgA decreased during cancer therapy which returned to 
the baseline level after termination of the treatment. The mean IgA was 70.5 
+/- 52.8 mg/mL at baseline, 35.8 +/- 15.0 mg/mL after radiotherapy with p – 
value less than 0.001. This may be due to various factors such as the age of 
the patients, the immune status of the patients and the duration between the 
completion of the treatment and the sample collection. 
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The present study showed a significant decrease in the salivary 
haptoglobin levels in treated oral cancer patients. The mean salivary 
haptoglobin in treated oral cancer patients was the lowest 1.285 ± 0.492 
mg/dL and the mean salivary haptoglobin was highest in patients with oral 
carcinoma 4.56 ± 1.19mg/dL with a p-value of 0.000. This is in accordance 
with the study conducted by Krasteva 200846 (p-value0.007). Krasteva.A et 
al in 200846 found that there was a significant decrease in the salivary 
haptoglobin in treated oral cancer patients when compared with the oral 
cancer patients with a p-value of 0.007. There is no sufficient data in the 
literature to emphasise the cause for the decrease in haptoglobin in patients 
treated for oral carcinoma. 
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The present study titled “Estimation of salivary immunoglobulins 
and acute phase proteins in patients with Potentially malignant disorders, 
Oral Cancer and Treated oral cancer” was conducted in the department of 
Oral Medicine and Radiology, Ragas Dental College, Uthandi, Chennai and 
Dr. Rai Memorial Medical and Cancer Centre, Chennai, to estimate the 
salivary levels of IgA, IgG, C-reactive protein and Haptoglobin in patients 
with potentially malignant disorders like leukoplakia and oral submucous 
fibrosis, oral cancer and treated oral cancer and to compare the values with 
the  control subjects. 
          A total of 80 individuals were selected for the study. Among the study 
subjects 20 patients were suffering from Potentially Malignant Disorders, 20 
patients were suffering from Oral Cancer, 20 were treated for Oral 
Carcinoma and 20 patients were normal controls. Informed consent was 
taken from all subjects before including them in the study. Participants with 
infectious diseases during one month before saliva sampling, active dental 
abcesses, and collagen vascular diseases were excluded from the study. 
The experimental subjects were made to sit comfortably on a Dental 
Chair.  Sterile hand gloves were used during examination of the patients.  
Patients were examined under halogen lamp in the dental chair under aseptic 
conditions and relevant demographic data were collected.  Clinical diagnosis 
was made and patients who showed characteristic features of Leukoplakia, 
Oral submucous fibrosis and Oral Cancer were prepared for sample 
collection. 
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 The patients were asked to rinse their mouth with water and were 
made to sit comfortably in a dental chair. Saliva was collected during a 15-
minutes interval by spitting method. This was pooled saliva and represented 
the output from all the salivary glands. 2-3mL of saliva was collected in 
sterile containers. All samples were kept in ice after collection and then 
centrifuged at 3000 rpm for 10 min to remove particulate materials and the 
supernatant was used for estimation of the immunoglobulins and acute 
phase proteins. 
The study documents the following data: 
 Among the 80 subjects 62(77.5%) were males and 18(22.5%) were 
females. The minimum age of the study subjects was 19 years and the 
maximum age was 75 years.  
 Among the 80 subjects 20(25%) had the habit of smoking, 
23(28.8%) had the habit of chewing, 12(15%) had the habit of chewing 
and smoking, 10(12.5%) had the habit of smoking and alcohol 
consumption, 1(1.3%) had the habit of chewing and alcohol 
consumption and 3(3.8%) had all the  three habits together with a p-
value of 0.000 which is statistically significant. Thus a positive 
correlation between smoking, chewing, alcohol consumption and 
development of precancer and cancer has been established. 
 
 
 
 
   Summary & Conclusion 
 
125 
 
 The most common site for leukoplakia was in the retro-commissure 
area with 7 (63.6%) subjects followed by buccal mucosa 2(18.2%) and 
one each in the tongue and floor of the mouth. 
 The present study showed all 9 cases of OSMF in the buccal mucosa 
with 5 (55.6%) in Grade III and 2 each in Grades I and IV and none in 
Grade II.  
 Among the total of 40 (100%) subjects in Groups II and III, 
11(27.5%) had carcinoma in the tongue, 17(42.5%) had in the buccal 
mucosa, 7(17.5%) had in the alveolar mucosa, 2(5%) had carcinoma in 
the floor of the mouth and 1(2.5%) in the palate and 2(5%) had in both 
the tongue and the floor of the mouth. 
 Elevated levels of salivary IgA, IgG, CRP and Haptoglobin were 
observed in patients with potentially malignant disorders like 
leukoplakia and oral submucous fibrosis. The mean salivary IgA in 
patients with potentially malignant disorders was 201.7 ± 76.01 µg/mL, 
the mean salivary IgG was 8.7± 4.07 µg/dL, mean salivary CRP was 
0.015± 0.036 µg/mL and the mean salivary haptoglobin was 1.43 ± 
0.843 mg/dL. In controls the mean salivary IgA was 72.87 ± 26.46 
µg/mL, the mean salivary IgG 6.58 ± 5.60 µg/dL,  the mean salivary 
CRP was 0.070 ± 0.13 mg/L and the mean salivary haptoglobin was 
1.91 ± 0.895 mg/dL. 
 There was a significant rise in the salivary IgA, IgG, and 
Haptoglobin and a slight elevation in the salivary CRP levels in patients 
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with oral carcinoma. The mean salivary IgA in patients with oral 
carcinoma was 253.35 ± 83.3µg/mL, the mean salivary IgG was 33.86 ± 
20.31mg/dL, mean salivary CRP was 0.050 ± 0.10 µg/mL and the mean 
salivary haptoglobin was 4.56 ± 1.19mg/dL. In controls the mean 
salivary IgA was 72.87 ± 26.46 µg/mL, the mean salivary IgG 6.58 ± 
5.60 µg/dL, the mean salivary CRP was 0.070 ± 0.13 mg/L and the 
mean salivary haptoglobin was 1.91 ± 0.895 mg/dL. 
 The salivary IgA, IgG and CRP in treated oral cancer patients 
remained significantly higher. The mean salivary IgA in patients with 
treated oral carcinoma was 76.26 ± 9.20 µg/mL, the mean salivary IgG 
was 17.74 ± 3.12 µg/dL and the mean salivary CRP was 0.120 ± 
0.128mg/L. In controls the mean salivary IgA was 72.87 ± 26.46 µg/mL, 
the mean salivary IgG 6.58 ± 5.60 µg/dL and the mean salivary CRP 
was 0.070 ± 0.13 mg/L. 
  A significant decrease in the salivary haptoglobin levels were 
observed in treated oral cancer patients. The mean salivary haptoglobin 
in treated oral cancer patients was 1.285 ± 0.492 mg/dL and the mean 
salivary haptoglobin in controls was 1.91 ± 0.895 mg/dL. 
           Thus the salivary IgA was found to be highest in patients with 
oral carcinoma followed by patients with potentially malignant 
disorders, then treated oral cancer patients and the controls having the 
lowest values. The salivary IgG was found to be highest in patients with 
oral carcinoma followed by patients treated for oral carcinoma, patients 
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with potentially malignant disorders and lowest in the controls. The 
salivary CRP was highest in the patients treated for oral carcinoma 
followed by controls, patients with oral carcinoma and lowest in patients 
with potentially malignant disorders. The salivary haptoglobin was 
highest in oral carcinoma patients followed by controls, patients with 
potentially malignant disorders and lowest in patients treated for oral 
carcinoma. 
  The increase of these salivary immunoglobulins and acute 
phase proteins in precancerous lesions and oral carcinoma may reflect 
the local inflammation accompanying the neoplastic process in the oral 
cavity or due to the direct transudation of these proteins from the blood 
or may be considered as a local defense mechanism against tumour 
development.  
  To conclude, a statistically significant difference was 
observed in relation to the tested parameters between the four different 
groups included in the study. Salivary analysis holds promise as a non-
invasive approach to identify biomarkers for human oral cancer. An 
extensive, well-executed study is required to ensure the practical 
usefulness of these biomarkers in screening for early oral cancer, 
possible recurrent disease and individuals with high risk of oral 
malignancy. Further studies should include a larger sample size to 
emphasize the sensitivity and specificity of these biomarkers so as to 
arrive at an early diagnosis aimed at the betterment of the patients. 
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MASTER CHART 
 
GROUP I – POTENTIALLY MALIGNANT LESIONS 
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1 
 
Madhan kumar 
 
27 
 
Male 
 
Chewing 
 
OSMF 132.92 7.6 0.1 1.1 
 
2 
 
Sagayam 
 
48 
 
Male 
 
Smoking 
 
Leukoplakia 156.24 1.3 0 2.8 
 
3 
 
Arumugam 
 
43 
 
Male 
Smoking 
Chewing 
 
Leukoplakia 287.8 14.7 0 2.4 
 
4 
 
Pushpalingam 
 
40 
 
Male 
Smoking 
Alcohol  
 
Leukoplakia 317.10 13.0 0 3.8 
 
5 
Mymoon 
Beevi 
 
36 
 
Female 
 
Chewing 
 
OSMF 113.76 5.5 0 1.6 
 
6 
 
Parthiban 
 
21 
 
Male 
Smoking 
Chewing 
 
Leukoplakia 150.84 15.8 0 2.4 
 
7 
 
Sangram 
 
24 
 
Male 
 
Chewing 
 
OSMF 142.63 15.0 0 1.8 
 
8 
 
Vijaya 
 
30 
 
Female 
 
Chewing 
 
OSMF 243.69 5.3 0 0.6 
 
9 
 
Ganesh 
 
38 
 
Male 
Smoking 
Alcohol  
 
Leukoplakia 133.9 6.9 0 0.7 
 
10 
 
Venkatesh 
 
24 
 
Male 
 
Chewing 
 
OSMF 161.55 15.3 0 1.2 
 
11 
 
Munuswamy 
 
72 
 
Male 
Smoking 
Alcohol  
 
Leukoplakia 180.6 9.6 0 1.0 
 
12 
 
Gopu 
 
75 
 
 
Male 
 
Smoking 
 
Leukoplakia 113.17 6.4 0 1.2 
 
13 
 
Arun 
 
27 
 
 
Male 
Smoking 
Chewing 
 
Leukoplakia 230.74 5.5 0 0.7 
 
14 
 
Vinayagam 
 
65 
 
 
Male 
 
Smoking 
 
Leukoplakia 237.13 5.3 0 0.9 
 
15 
 
Prakash 
 
24 
 
 
Male 
 
Chewing 
 
OSMF 241.6 9.2 0 0.7 
 
16 
 
Thanikachalam 
 
24 
 
 
Male 
 
Chewing 
 
OSMF 108.79 9.2 0 0.8 
 
17 
 
Selvam 
 
33 
 
 
Male 
Chewing 
Alcohol  
 
OSMF 161 5.9 0 0.8 
 
18 
 
Basha 
 
40 
 
 
Male 
 
Chewing 
 
OSMF 296.6 8.1 0.1 1.1 
 
19 
 
Muralikumar 
 
24 
 
 
Male 
Smoking 
Chewing 
 
Leukoplakia 361.37 8.9 0 1.7 
 
20 
 
Tamilmani  
 
69 
 
Male 
 
Smoking 
 
Leukoplakia 262.8 5.5 0.1 1.3 
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GROUP II – ORAL CARCINOMA 
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1 
 
Vatchala 
 
42 
 
Female 
 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
141.44 22 0.1 6.2 
 
2 
 
Sridharan 
 
44 
 
Male  
 
Smoking 
 
Tongue 125.71 15.2 0 3.7 
 
3 
 
Ramakrishnan 
 
42 
 
Male 
 
Smoking 
Chewing 
 
Tongue 338.98 20 0 3.5 
 
4 
 
Subramaniyan 
 
61 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
380.34 11 0 3.5 
 
5 
 
Arogyadass 
 
47 
 
Male 
 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
273.73 29 0.2 3.1 
 
6 
 
Radhakrishnan 
 
56 
 
Male 
Smoking 
Chewing 
Alcohol 
 
Buccal 
mucosa 
124.42 55.8 0.1 5.0 
 
7 
 
Selvaraj 
 
63 
 
Male 
 
Smoking 
Alcohol 
Tongue 
& 
Floor of 
the 
mouth 
139.23 12.0 0 3.3 
 
8 
 
Guruswamy 
 
35 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
268.23 14.2 0 4.4 
 
9 
 
Selvaraj 
 
40 
 
Male 
 
Smoking 
Alcohol 
 
Buccal 
mucosa 
246.09 23.3 0 4.1 
 
10 
 
 
Godavari 
 
53 
 
Female 
 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
330.23 18.8 0 5.5 
 
11 
 
Vetrivel 
 
60 
 
Male 
 
Smoking 
Chewing 
 
Buccal 
mucosa 
208.66 4.1 0 3.9 
 
12 
 
Madurai Muthu 
 
55 
 
Male 
 
Smoking 
Chewing 
 
Tongue 237.33 53.4 0 4.1 
 
13 
 
Yesammal 
 
50 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
250.42 57.0 0 3.6 
 
14 
 
Kumarappan 
 
33 
 
Male 
 
Smoking 
 
Tongue 273.08 68.3 0 7.4 
 
15 
 
Kabir 
 
37 
 
Male 
 
Smoking 
Alcohol 
 
Palate  356.07 55.0 0.4 6.3 
 
16 
 
Padmavathy 
 
40 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
365.78 48.6 0.1 5.8 
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17 
 
Varadharajan 
 
45 
 
Male 
Smoking 
Chewing 
Alcohol 
 
Floor of 
the 
mouth 
295.74 52.3 0 3.7 
 
18 
 
Jawahar 
 
60 
 
Male 
 
Chewing 
 
Floor of 
the 
mouth 
153.45 66 0 5.5 
 
19 
 
Mary 
 
38 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
234.46 14.5 0.1 3.9 
 
20 
 
Chandrasekaran 
 
67 
 
Male 
 
Smoking 
 
Tongue 324.64 25.7 0 4.8 
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GROUP III – TREATED ORAL CARCINOMA 
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1 
 
Ramanathan 
 
62 
 
Male 
 
Smoking 
 
Tongue 67.45 25.4 0 1.4 
 
2 
 
Sethuraman 
 
69 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
82.0 16.7 0 2.2 
 
3 
 
Vaidyanathan 
 
24 
 
Male 
 
Smoking 
Alcohol 
Alveolar 
mucosa 
& buccal 
sulcus 
62.3 15.4 0.1 1.5 
 
4 
 
Renuka 
 
34 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
73.4 18.5 0.1 0.4 
 
5 
 
Logu 
 
49 
 
Male 
Smoking 
Chewing 
Alcohol 
 
Tongue 66.0 16 0.4 0.7 
 
6 
 
Abhraham 
 
42 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
72.65 25.0 0.2 1.8 
 
7 
 
Murugan 
 
39 
 
Male 
 
Smoking 
Alcohol 
 
Tongue 79.78 16.5 0.1 2 
 
8 
 
Venkatesh 
 
30 
 
Male 
 
Smoking 
 
Tongue 64.5 17.5 0 1.4 
 
9 
 
Devendran 
 
55 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
79.8 14.6 0 0.8 
 
10 
 
Pachaiammal 
 
57 
 
Female 
 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
68.4 13.8 0.2 0.5 
 
11 
 
Madhan 
 
31 
 
Male 
 
Smoking 
Chewing 
 
Buccal 
mucosa 
78.4 17.4 0.1 1.7 
 
12 
 
Kadeeresan 
 
70 
 
Male 
 
Smoking 
Alcohol 
 
Buccal 
mucosa 
89.0 17.57 0.1 1.5 
 
13 
 
Soorya 
Narayanan 
 
36 
 
Male 
 
Smoking 
Chewing 
 
Tongue 98.3 18.4 0.4 1.0 
 
14 
 
Manjula 
 
42 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
83.7 21.30 0.2 1.8 
 
15 
 
Mukesh 
kumar 
 
40 
 
Male 
 
Smoking 
 
Buccal 
mucosa 
79.2 20.2 0.1 1.3 
 
16 
 
Duraivel 
 
65 
 
Male 
 
Chewing 
 
Tongue 
& 
Floor of 
the 
mouth 
77.8 15.0 0 1.6 
 
17 
 
Mary 
Fernandes 
 
53 
 
Female 
 
Chewing 
 
Tongue 75.28 17.6 0 1.4 
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18 
 
Pandiyan 
 
40 
 
Male 
 
Smoking 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
87.8 15.0 0.1 1.8 
 
19 
 
Devi 
 
60 
 
Female 
 
Chewing 
Alveolar 
mucosa 
& buccal 
sulcus 
72.8 16.3 0.3 1.5 
 
20 
 
Sakunthala 
 
43 
 
Female 
 
Chewing 
 
Buccal 
mucosa 
67 16.7 0 0.4 
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GROUP IV – CONTROL GROUP 
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1 
 
Vinodh 
 
28 
 
Male  
 
Smoking 
 
88.21 27.9 0.5 0.8 
 
2 
 
Kamarunisha 
 
25 
 
Female 
 
- 107 4.8 0 1.7 
 
3 
 
Vedachalem 
 
60 
 
Male 
 
- 109.2 6.0 0.1 2.0 
 
4 
 
Krishnan 
 
53 
 
Male 
 
- 
 
47.6 8.2 0.1 1.2 
 
5 
 
Yuga 
 
19 
 
Male 
 
Chewing 43.7 5.5 0 1.3 
 
6 
 
Issac 
 
41 
 
Male 
 
Smoking 
Alcohol  
33.3 5.4 0.1 2.2 
 
7 
 
Sundareshwaran 
 
36 
 
Male 
 
- 79 6.7 0 1.5 
 
8 
 
Prakash 
 
40 
 
Male 
 
Smoking 40.3 5.6 0 1.0 
 
9 
 
Rajasekaran 
 
68 
 
Male 
 
- 32.6 6.5 0 1.3 
 
10 
 
Juliya 
 
26 
 
Female 
 
- 43.3 3.4 0 2.2 
 
11 
 
Guru 
 
35 
 
Male 
 
Smoking 
Chewing 
40.6 3.7 0 2.7 
 
12 
 
Selvam 
 
33 
 
Male 
 
Smoking 83.6 1.5 0.3 1.7 
 
13 
 
Lakshmi 
 
50 
 
Female 
 
- 103 3.8 0 0.9 
 
14 
 
Muthukumar 
 
39 
 
Male 
 
- 82.7 5.5 0.2 4 
 
15 
 
Gopu 
 
23 
 
Male 
 
- 74.84 10.3 0 3.3 
 
16 
 
Rajendran 
 
65 
 
Male 
 
- 103.85 2.8 0 3.5 
 
17 
 
Devaraj 
 
58 
 
Male 
 
Smoking 87.78 7.2 0 1.0 
 
18 
 
Preetham 
 
40 
 
Male 
 
Smoking 81.67 1.3 0 1.9 
 
19 
 
Saraswathi 
 
30 
 
Female 
 
Chewing 81.2 3.0 0.1 1.7 
 
20 
 
Baby  
 
44 
 
Female  
 
- 94.24 13.5 0 2.3 
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PROFORMA 
 
 
RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, EAST COAST ROAD, UTHANDI, CHENNAI – 600 119. 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
 
Estimation of salivary immunoglobulin and acute phase proteins in 
patients with potentially malignant disorders, untreated and treated 
oral cancer.  
 
Serial no.                                                                Op. no.   
Name:                                                                     Age/ Sex:   
Religion:  
Occupation:                                                            Income:  
Address:                                                                  Phone no:  
   
   
HABITS 
 
PRESENT 
 
ABSENT 
 
Smoking 
    
 
Chewing 
    
 
Alcohol 
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          LESION 
   
PRESENT
   
ABSENT 
Potentially malignant 
disorders 
    
Untreated Oral Squamous 
Cell Carcinoma 
    
Treated Oral Squamous Cell 
carcinoma 
    
   
Date of sample collection:  
PARAMETERS/ 
 
LESION 
SALIVARY 
IgA 
(mg/l) 
SALIVARY 
IgG 
(mg/l) 
SALIVARY 
CRP 
(mg/l) 
SALIVARY 
HAPTOGLOBIN 
(mg/l) 
Potentially 
malignant 
disorders 
        
Untreated Oral 
Squamous Cell 
Carcinoma 
        
Treated Oral 
Squamous Cell 
carcinoma 
        
                                                                                                      
 
 
 
Annexure III 
 
150 
 
 
CONSENT FORM 
CONSENT LETTER 
 
I __________ the undersigned hereby give my consent for the performance of diagnostic test on 
myself “to evaluate the prognostic value of salivary immunoglobulin and acute phase proteins in 
potentially malignant disorders and in oral cancer” conducted by Dr. S. Aswini under the able 
guidance of Dr. S. Shanmugam M.D.S., Professor and HOD, Department of Oral Medicine and 
Radiology, Ragas Dental College and Hospital, Chennai. I have been informed and explained the 
status of my disorder, evaluation procedure, risk involved and likelihood of success. I also understand 
and accept this as a part of study protocol, thereby voluntarily, unconditionally, freely give my 
consent without any fear or pressure in mentally sound and conscious state to participate in the study. 
 
 
 
Witness/ Representative                                                                            Patient signature  
         ( If any)                                    
                                                                                                                   Date: 
 
 
åð¢¹îô¢ ð®õñ¢ 
 
 
 ªêù¢¬ù, ó£è£ú¢ ðô¢ñ¼î¢¶õè¢èô¢Öó¤ ñø¢Áñ¢ ñ¼î¢¶õñ¬ùò¤ù¢ õ£ò¢ 
ñ¼î¢¶õñ¢ ñø¢Áñ¢ á´èî¤ó¢ ¶¬øò¤ù¢ î¬ôõó¢ ñø¢Áñ¢ «ðó£ê¤ó¤òó¢ ñ¼. S. êí¢ºèñ¢ 
Üõó¢è÷¤ù¢ «ñø¢ð£ó¢¬õò¤ô¢, º¶ï¤¬ô (MDS) ðì¢ìð®ð¢¹ ÀÂ¢Öõ ñ¼. S. Üú¢õ¤ù¤ 
Üõó¢è÷¢ «ñø¢ªè£÷¢Àñ¢ õ£ò¢¹ø¢Á «ï£ò¢ à÷¢÷õó¢è÷¢ ñø¢Áñ¢ Üîø¢è£ù 
ê£î¢î¤òÃÁ à÷¢÷õó¢è÷¢ âù¢ø ð¤£¤¾è÷¤ô¢ à÷¢÷ «ï£ò£÷¤è÷¤ù¢ àñ¤ö¢ï¦ó¤ù¢ 
ðô¢«õÁ îù¢¬ñè¬÷ Ýó£ò¢ï¢¶ ð£ó¢è¢è ïìî¢¶ñ¢ Ýó£ò¢ê¢ê¤ø¢è£ù ðó¤«ê£î¬ùèÀè¢° 
âù¢¬ù àì¢ð´î¢¶õîø¢°___________________âù¢è¤ù¢ø ï£ù¢ âù¶ ñùº¾ï¢î ðó¤Ìóí 
êñ¢ñîî¢î¤¬ù Ü÷¤è¢è¤«øù¢. 
 
 «ñ½ñ¢ âùè¢° âù¢Â¬ìò «ï£ò¤ù¢ îù¢¬ñ¬òð¢ ðø¢ø¤»ñ¢, Þð¢ðó¤«ê£î¬ù 
ðø¢ø¤»ñ¢, Üîù£ô¢ ãø¢ðìè¢Ã®ò õ¤¬÷¾è¬÷ð¢ ðø¢ø¤»ñ¢ â´î¢¶ Ãøð¢ðì¢´÷¢÷¶ 
âù¾ñ¢, Þï¢î ðó¤«ê£î¬ùè¢°, ï£ù¢ âï¢îõ¤î Üê¢êºñ¤ù¢ø¤ îù¢ù¤ê¢¬êò£è¾ñ¢, ªî÷¤õ£ù 
º¿ñù¶ìù¢ âù¢Â¬ìò ðó¤Ìóí êñ¢ñî¤î¢î¬ù Ü÷¤è¢è¤«øù¢ âù Þîù¢ Íôñ¢ 
ªîó¤òð¢ð´î¢¶è¤«øù¢.        
            
                                                                                           Þð¢ð®è¢° 
ê£ì¢ê¤ò£÷ó¢è÷¢ 
 
 
 
 
ªêù¢¬ù  
«îî¤   
 
 
 
 
 
